ࡱ> $[bjbj$ 6D4777h 3+$7pW<>)e4eeefvgLg(Mkffkkeeʥʥʥk2ee.ʥkʥʥnVe~pk7p:0:^l@VVlgh|ʥidxigggʥgggkkkkggggggggg :$december 2009 OBRAZEC ZA ODOBRITEV SPREMEMBE DOVOLJENJA ZA PROMET ALI SPREMEMBE PREDLO}ENE DOKUMENTACIJE zdravila za uporabo v humani medicini  FORMCHECKBOX zdravila za uporabo v veterinarski medicini  FORMCHECKBOX   FORMCHECKBOX  NACIONALNO DOVOLJENJE PO POSTOPKU Z MEDSEBOJNIM PRIZNAVANJEM `tevilka/e sprememb/e1: ....................  FORMCHECKBOX  DOVOLJENJE PO CENTRALIZIRANEM POSTOPKU  FORMCHECKBOX  NACIONALNO DOVOLJENJE Referen na dr~ava lanica / Referen ni pristojni organ v postopku z delitvijo dela  FORMCHECKBOX AT  FORMCHECKBOX BE  FORMCHECKBOX BG  FORMCHECKBOX CY  FORMCHECKBOX CZ  FORMCHECKBOX DE  FORMCHECKBOX DK  FORMCHECKBOX EE  FORMCHECKBOX EL  FORMCHECKBOX ES  FORMCHECKBOX FI  FORMCHECKBOX FR  FORMCHECKBOX HU  FORMCHECKBOX IE  FORMCHECKBOX IS FORMCHECKBOX IT  FORMCHECKBOX LI  FORMCHECKBOX LT  FORMCHECKBOX LU  FORMCHECKBOX LV  FORMCHECKBOX MT  FORMCHECKBOX NL  FORMCHECKBOX NO  FORMCHECKBOX PL  FORMCHECKBOX PT  FORMCHECKBOX RO  FORMCHECKBOX SE  FORMCHECKBOX SI  FORMCHECKBOX SK  FORMCHECKBOX UK  FORMCHECKBOX EMA Zadevna/e dr~ava/e lanica/e  FORMCHECKBOX AT  FORMCHECKBOX BE  FORMCHECKBOX BG  FORMCHECKBOX CY  FORMCHECKBOX CZ  FORMCHECKBOX DE  FORMCHECKBOX DK  FORMCHECKBOX EE  FORMCHECKBOX EL  FORMCHECKBOX ES  FORMCHECKBOX FI  FORMCHECKBOX FR  FORMCHECKBOX HU  FORMCHECKBOX IE  FORMCHECKBOX IS FORMCHECKBOX IT  FORMCHECKBOX LI  FORMCHECKBOX LT  FORMCHECKBOX LU  FORMCHECKBOX LV  FORMCHECKBOX MT  FORMCHECKBOX NL  FORMCHECKBOX NO  FORMCHECKBOX PL  FORMCHECKBOX PT  FORMCHECKBOX RO  FORMCHECKBOX SE  FORMCHECKBOX SI  FORMCHECKBOX SK  FORMCHECKBOX UK FORMCHECKBOX nobena Vrsta vloge (ozna ite):  FORMCHECKBOX  tip IAIN  FORMCHECKBOX  tip IA  FORMCHECKBOX  tip IB nepredvidena2  FORMCHECKBOX  tip IB predvidena2  FORMCHECKBOX  tip II  FORMCHECKBOX  tip II  29. len3  FORMCHECKBOX  posamezna sprememba  FORMCHECKBOX  zdru~evanje sprememb v skupine  FORMCHECKBOX vklju uje razairitev dovoljenja za promet (DzP)4  FORMCHECKBOX  delitev dela Sprememba/e zadeva/jo (le za spremembe tipa IB in tipa II, ozna ite vse zadevne spremembe):  FORMCHECKBOX  indikacijo  FORMCHECKBOX  indikacijo za uporabo v pediatriji  FORMCHECKBOX  varnost  FORMCHECKBOX  posledica nujnega varnostnega ukrepa  FORMCHECKBOX  kakovost  FORMCHECKBOX  letno spremembo za cepiva proti humani gripi  FORMCHECKBOX  ~ivalske vrste, ki niso namenjene za proizvodnjo ~ivil  FORMCHECKBOX  drugo1 Zdravila za uporabo v humani medicini: `tevilko izpolni imetnik dovoljenja za promet z zdravilom, pri emer mora upoatevati pravilno zaporedno atevilko postopka z medsebojnim priznavanjem glede na 1. poglavje navodil "Best Practice Guides for the submission and processing of variations in the Mutual Recognition Procedure" (HYPERLINK "http://www.hma.eu"http://www.hma.eu). Zdravila za uporabo v veterinarski medicini: tevilko spremembe mora izdati referen na dr~ava lanice pred vlo~itvijo vloge v skladu z navodilom  VMRFG Best Practice Guide (HYPERLINK "http://www.hma.eu"http://www.hma.eu). Centralizirani postopek: Navedite zaporedno atevilko EMA postopka, e je znana (ne interne atevilke imetnika DzP). V postopku delitve dela z EMA kot referen nim organom navedite EMA atevilko postopka delitve dela ( high level ). 2  Nepredvidena sprememba je sprememba, ki ni manjaa sprememba tipa IB v skladu s smernico Evropske komisije o razvra anju sprememb, ali ki ni razvra ena kot sprememba tipa IB v skladu s 5. lenom Uredbe Komisije (ES) at. 1234/2008. e en ali ve  pogojev za spremembo tipa IA v zadevni smernici niso izpolnjeni, se lahko sprememba vlo~i kot sprememba tipa IB, razen e je sprememba razvra ena kot ve ja sprememba tipa II. 3 Sprememba tipa II, vlo~ena v skladu z 29. lenom Uredbe (ES) at. 1901/2006. 4 e so spremembe zdru~ene v skupino sprememb, ki vklju uje razairitev DzP, je ta obrazec dodatek k obrazcu za razairitev DzP. Ime in naslov predlagatelja/imetnika dovoljenja za promet5:Ime in naslov kontaktne osebe6: Telefon: Faks (neobvezno): E-poata: 5 Pri spremembah z delitvijo dela ali zdru~enih spremembah tipa IA, ki zadevajo ve  kot eno DzP, navedite referen nega imetnika DzP, ki bo vodil postopek v imenu vseh imetnikov DzP. 6 Kot je navedeno v razdelku 2.4.3 Dela IA/Modula 1 obrazca za pridobitev DzP. e je druga, prilo~ite pooblastilo. Pri spremembah z delitvijo dela ali zdru~enih spremembah tipa IA, ki zadevajo ve  kot eno DzP, navedite le eno kontaktno osebo (glejte tudi razdelek s podpisniki na koncu obrazca). ZADEVNA ZDRAVILA 7 (Izmialjeno/a) ime/na:Zdravilna/e u inkovina/eFarmacevtska oblika JakostImetnik/i DzP: `tevilka/e DzP: 8MRP atevilka spremembe87 e je seznam zelo dolg (ve  kot ena stran), ga lahko predlo~ite kot dodatek k obrazcu. Za zdravila, ki so DzP pridobila po centraliziranem postopku, predlo~ite kot dodatek k obrazcu Prilogo A. Za postopke z delitvijo dela predlo~ene na EMA, ki vklju ujejo zdravila, ki so DzP pridobila po nacionalnem postopku, navedite zadevna zdravila in specifi ne podatke dr~ave lanice (vklju no s atevilko spremembe) v Prilogi B k temu obrazcu (uporabite predlogo na spletni strani EMA). 8 Navedite atevilko/e dovoljenj/a za promet. Za atevilko MRP spremembe, ki je specifi na za zdravilo, glejte smernico  The Best Practice Guide on Variations , 1. poglavje, razdelek 2, primer: NL/H/0123/001-004/IB/033/G TIP/I SPREMEMB/E  FORMCHECKBOX  Predlo~ena je kopija ustrezne/ih strani iz smernice Evropske komisije o razvra anju za zadevno/e spremembo/e in ustrezno ozna ena okenca z izpolnjenimi pogoji in predlo~eno dokumentacijo (tako za spremembe tipa IA kot tipa IB) Spremembe, vklju ene v tej vlogi: `tevilka in naslov spremembe v skladu z razvrstitvijo v smerniciTip spremembe FORMCHECKBOX a)Dolo ena sprememba iz smernice tip(V ta razdelek vklju ite ustrezno/e spremembo/e iz seznama na koncu obrazca (kjer so na voljo podrobnejaa navodila). Zgornji primer in seznam sprememb na koncu obrazca izbriaite iz izpolnjenega obrazca. Ta razdelek je lahko izpolnjen v angleakem jeziku). vzrok in utemeljitev spremembe, utemeljitev zdru~evanja sprememb, delitve dela in razvrstitve nepredvidenih sprememb ( e je potrebno) (Opis in vzrok predlaganih sprememb. V primeru zdru~evanja sprememb in delitve dela, podajte ustrezno obrazlo~itev v samostojnem odstavku. V primeru nepredvidene spremembe, predlagano razvrstitev spremembe ustrezno obrazlo~ite).  SEDANJE STANJE 10,11PREDLOG 10, 11  10 Razlo~ite natan no ~e odobreno in predlagano besedilo ali specifikacijo, vklju no s atevilko poglavja iz dokumentacije na najni~ji mo~ni ravni. 11 Pri spremembah v povzetku glavnih zna ilnosti zdravila, navodilu za uporabo in na ovojnini, pod rtajte ali s krepko pisavo poudarite spremenjene besede ali predlo~ite kot lo eno prilogo k temu obrazcu. DRUGE VLOGE 12 12 Zaradi zahtevnosti v primeru sprememb z delitvijo dela ali zdru~enih sprememb tipa IA, ki zadevajo ve  kot eno DzP, tega razdeka ni potrebno izpolniti. Spremembe tipa II  nove indikacije  podatki o zdravilu siroti: (Le za zdravila za uporabo v humani medicini; izbriaite ta razdelek, e se sprememba ne nanaaa na novo indikacijo) ali je bila za to novo indikacijo vlo~ena vloga za dolo itev zdravila sirote? SYMBOL 166 \f "Wingdings" Ne SYMBOL 166 \f "Wingdings" Da `tevilka postopka za dolo itev zdravila sirote: FORMTEXT       SYMBOL 166 \f "Wingdings" V postopku SYMBOL 166 \f "Wingdings" Zdravilo je bilo dolo eno za zdravilo siroto: Datum (dan-mesec-leto) :  FORMTEXT       Na podlagi merila  pomembna korist": SYMBOL 166 \f "Wingdings" Da SYMBOL 166 \f "Wingdings" Ne `tevilka iz EU Registra zdravil sirot: FORMTEXT        FORMCHECKBOX Prilo~ite kopijo odlo be o dolo itvi podatki o tr~ni zaa iti zdravila sirote Ali je bilo katerokoli zdravilo dolo eno kot zdravilo sirota za terapevtsko indikacijo, ki je predmet te vloge?13 SYMBOL 166 \f "Wingdings" Ne SYMBOL 166 \f "Wingdings" Da Prosimo, navedite atevilko/e EU odlo b/e o dolo itvi zdravil/a sirot/e: FORMTEXT       e ste odgovorili pritrdilno, ali je bilo za katerokoli zdravilo, dolo eno za zdravilo siroto, izdano dovoljenje za promet v EU? SYMBOL 166 \f "Wingdings" Ne SYMBOL 166 \f "Wingdings" Da Prosimo, navedite: ( Ime, jakost, farmacevtska oblika odobrenega zdravila:  FORMTEXT       ( Ime imetnika dovoljenja za promet: FORMTEXT       ( `tevilka/e dovoljenja/dovoljenj za promet: ( Datum pridobitve dovoljenja za promet (dan-mesec-leto):  FORMTEXT       e ste odgovorili pritrdilno, ali se zdravilo, ki je predmet te vloge, ateje za  podobno zdravilo ~e odobrenemu zdravilu siroti? (kot je opredeljeno v 3. lenu Uredbe Komisije (ES) at. 847/2000) SYMBOL 166 \f "Wingdings" Ne (predlo~ite ustrezne dokumente 1.7.1 v Modulu 1) SYMBOL 166 \f "Wingdings" Da (predlo~ite ustrezne dokumente 1.7.1 in 1.7.2 v Modulu 1) 13 Kot je objavila Evropska komisija (HYPERLINK "http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm"http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm) Spremembe tipa II zahteve v pediatriji: (Le za zdravila za uporabo v humani medicini; izpolnite le pri spremembah, ki se nanaajo na novo indikacijo ali pri spremembah, povezanih z uveljavitvijo na rta pediatri nih raziskav (PIP)) (Opomba: Pri zdravilih, ki so last istega14 imetnika DzP, je treba upoatevati pojem krovnega dovoljenja za promet, kot je opredeljen v 2. pododstavku 6(1) lena Direktive 2001/83/ES z vsemi spremembami) SYMBOL 166 \f "Wingdings" 8. len Pediatri ne uredbe velja za to vlogo, ker: (Opomba: Ne velja za zdravila z dobro uveljavljeno uporabo, generi na zdravila, zdravila na podlagi hibridne vloge, podobna bioloaka zdravila in za tradicionalna zdravila rastlinskega izvora) SYMBOL 166 \f "Wingdings" Vloga se nanaaa na novo indikacijo ~e odobrenega zdravila, ki: SYMBOL 166 \f "Wingdings" je zaa iteno z dodatnim varstvenim certifikatom po Uredbi (EGS) at. 1768/92 SYMBOL 166 \f "Wingdings" je zaa iteno s patentom, na podlagi katerega je upravi ena dodelitev dodatnega varstvenega certifikata SYMBOL 166 \f "Wingdings" Vloga se nanaaa na predhodni/potekajo i/vzporedni postopek, ki je vezan na uporabo 8. lena Pediatri ne uredbe. `tevilka postopka pristojnega organa / EMA: SYMBOL 166 \f "Wingdings" Ta vloga ne sodi v obseg 8. lena Pediatri ne uredbe. SYMBOL 166 \f "Wingdings" Ta vloga se nanaaa na zdravila, za katera velja 7. len Pediatri ne uredbe. SYMBOL 166 \f "Wingdings" Ta vloga se nanaaa na novo indikacijo za Dovoljenje za promet z zdravilom za pediatri no uporabo (PUMA). SYMBOL 166 \f "Wingdings" Ta vloga se nanaaa na paediatri ne atudije, predlo~ene v skladu s 45. ali 46. lenom Pediatri ne uredbe. Vloga vsebuje: SYMBOL 166 \f "Wingdings" PIP `tevilka/e odlo itve o PIP: SYMBOL 166 \f "Wingdings" Opustitev, specifi no za zdravilo `tevilka odlo itve o opustitvi: SYMBOL 166 \f "Wingdings" Opustitev za skupino zdravil `tevilka odlo itve o opustitvi: FORMTEXT       (Opomba: Kopijo odlo itve o PIP/odlo itve o opustitvi vklju ite v Modul 1.10) Ali je za to vlogo potrjena skladnost s PIP? SYMBOL 166 \f "Wingdings" Ne SYMBOL 166 \f "Wingdings" Da e ste odgovorili pritrdilno, navedite: SYMBOL 166 \f "Wingdings" `tevilko mnenja o skladnosti PDCO:  FORMTEXT       SYMBOL 166 \f "Wingdings" Sklic na pristojni organ/dokument EMA:  FORMTEXT       (Opomba: e so na voljo, kopijo mnenja in poro ilo PDCO, dokument, ki ga je izdal nacionalni pristojni organ/EMA, ali predlagateljevo poro ilo o skladnosti, vklju ite v Modul 1.10)  FORMCHECKBOX  Prosimo predlo~ite tabelari ni povzetek rezultatov PIP v Modulu 1.10 14  Isti imetnik dovoljenja za promet z zdravilom skladno s sporo ilom Evropske komisije (98/C 299/03) pomeni, da pripada isti mati ni dru~bi ali skupini dru~b ali je z mati no dru~bo v ustreznem pogodbenem razmerju (npr. licenca). Spremembe tipa II  podaljaanje podatkovne/tr~ne zaa ite: (Izbriaite ta razdelek, e ni potreben) vloga v skladu z naslednjimi leni Direktive 2001/83/ES ali Uredbe (ES) 726/2004: SYMBOL 166 \f "Wingdings" 10(1) len Direktive 2001/83/ES / 14(11) len Uredbe (ES) at. 726/2004 (eno leto tr~ne zaa ite za novo indikacijo) SYMBOL 166 \f "Wingdings" 10(5) len Direktive 2001/83/ES (eno leto podatkovne zaa ite za novo indikacijo) SYMBOL 166 \f "Wingdings" 74(a) len Direktive 2001/83/ES (eno leto podatkovne zaa ite za spremembo razvrstitve zdravila) (Opomba: Poro ilo, ki utemeljuje zahtevo za podaljaanje podatkovne/tr~ne zaa ite, predlo~ite v Modulu 1.5.3) Prilagamo naslednje predloge sprememb informacij o zdravilu v ustreznih poglavjih dokumentacije, e je potrebno (Priloga):  FORMCHECKBOX  Povzetek glavnih zna ilnosti zdravila  FORMCHECKBOX  Imetnik dovoljenja za izdelavo, odgovoren za sproa anje serij in pogoji dovoljenja za promet15  FORMCHECKBOX  Besedilo zunanje in sti ne ovojnine  FORMCHECKBOX  Navodilo za uporabo  FORMCHECKBOX  Osnutek ovojnine16  FORMCHECKBOX  Vzorec16 15 Le za zdravila, ki so DzP pridobila po centraliziranem postopku (Dodatek II dovoljenja Skupnosti) 16 Glejte poglavje 7 Zvezka 2A ali 6A obvestil predlagateljem (Notice to Applicants) Izjava predlagatelja: Spodaj podpisani priglaam/vlagam prej navedene spremembe dovoljenj/a za promet in izjavljam, da: (ozna ite ustrezno okence)  FORMCHECKBOX  ni nobenih drugih sprememb kot so predlo~ene v tej vlogi (razen tistih, ki smo jih vlo~ili vzporedno in smo jih navedli v razdelku 'Druge vloge );  FORMCHECKBOX  so izpolnjeni vsi pogoji za zadevno/e spremembo/e, e je to potrebno;  FORMCHECKBOX  smo za priglasitev sprememb tipa IA predlo~ili zahtevano dokumentacijo;  FORMCHECKBOX  smo pla ali stroake postopka;  FORMCHECKBOX  smo spremembo/e predlo~ili hkrati v referen ni in vseh zadevnih dr~avah lanicah (za zdravila po postopku z medsebojnim priznavanjem ali postopku z delitvijo dela), ali tako EMA kot (so-) poro evalcu za zdravila po centraliziranem postopku ali v primeru, da je v postopek z delitvijo dela vklju ena EMA, tako RMS/CMS kot EMA;  FORMCHECKBOX  za spremembe v postopku z delitvijo dela ali za zdru~ene spremembe tipa IA, ki zadevajo ve  kot eno DzP: zadevna DzP pripadajo istemu imetniku. Spremembo/e bomo uveljavili17:  FORMCHECKBOX  Pri naslednji proizvodni seriji/naslednjem tiskanju  FORMCHECKBOX  Datum: ______________________ 17 Izpolnjeno mora biti le za spremembe tipa IB in tipa II. Pla ali smo stroake postopka v znesku18: __________________________________________________________ Navedite ustrezen len Pravilnika o stroakih18 : ________________________________  Glavni podpisnik19_________________ Natisnjeno ime _________________________________  FORMCHECKBOX  Pri postopkih z delitvijo dela/zdru~evanju sprememb za ve  kot eno DzP: glavni podpisnik, ki ima pooblastilo, da podpie v imenu kontaktnih oseb, ki so za vsa zadevna DzP navedena v razdelku 2.4.3 Dela IA/Modula 1 Obrazcev za pridobitev DzP. Drugi podpisnik __________________________ Natisnjeno ime ____________________________  Opis funkcije: ________________________ Datum:_______________________________ Opis funkcije: ________________________ Datum:___________________________ 18 Za vloge, predlo~ene na EMA (ki vklju ujejo postopke z delitvijo dela za zdravila, ki so pridobila DzP po postopku z medsebojnim priznavanjem), ti podatki niso obvezni. 19 Glavni podpisnik je obvezen. LIST OF VARIATIONS (to be deleted upon completion of the form) Please select the applicable variation(s) from the list presented below and include in the section Type(s) of Change(s) Variations included in this application above, in accordance with the following instructions: Only the main header of the change with the variation applied for needs to be included. To apply for variations not foreseen in the guideline, MAHs should declare such other variation (z) under the specific guideline section concerned at the lowest possible level i.e. either within a specific variation or under the appropriate guideline section title, as appropriate, including its proposed classification. Please indicate whether the variation has been subject to an Article 5 procedure. Examples of such z) variations have been already included in a number of relevant variations and section titles, for convenience. For Type IA variations the date of implementation by the MAH needs to be added in the last column. Full details on the precise scope of the variation concerned, should be given in the section precise scope of the application form. Examples of how the variation(s) should be presented in the section Type(s) of Change(s) of the application form. E.g. when applying for a change outside the approved specification limits for the active substance: B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substanceProcedure type FORMCHECKBOX f)Change outside the approved specifications limits range for the active substanceII E.g. when applying for an unforeseen change concerning specification limits for the active substance: B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substanceProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 E.g. when applying for an unforeseen change concerning the control of active substance: B.I.b Change in control of the active substanceProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 The full list of variations is to be deleted from the actual submitted application form. A. Administrative changeProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  Procedure type FORMCHECKBOX A.1Change in the name and/or address of the marketing authorisation holder FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. A.2 Change in the (invented) name of the medicinal productProcedure type FORMCHECKBOX a)for Centrally Authorised products FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)for Nationally Authorised ProductsIB9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX A.3Change in name of the active substance FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX A.4Change in the name and/or address of a manufacturer (including where relevant quality control sites) or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the product dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. A.5 Change in the name and/or address of a manufacturer of the finished product, including quality control sitesProcedure type FORMCHECKBOX a)Manufacturer responsible for batch release FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b) All other FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX A.6Change in ATC Code / ATC Vet Code FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX A.7Deletion of manufacturing sites (including for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)). FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.a Change in manufacture of the active substanceProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossierProcedure type FORMCHECKBOX a)The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer. FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Introduction of a new manufacturer of the active substance that is supported by an ASMFII FORMCHECKBOX c)The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions, which may have a potential to change important quality characteristics of the active substance, such as qualitative and/or quantitative impurity profile requiring qualification, or physico-chemical properties impacting on bioavailability.II FORMCHECKBOX d)New manufacturer of material for which an assessment is required of viral safety and/or TSE risk II FORMCHECKBOX e)The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product.II FORMCHECKBOX f)Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.a.2 Changes in the manufacturing process of the active substanceProcedure type FORMCHECKBOX a)Minor change in the manufacturing process of the active substance FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product.II FORMCHECKBOX c)The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol.II FORMCHECKBOX d)The change relates to a herbal medicinal product and there is a change to any of the following: geographical source, manufacturing route or production.II FORMCHECKBOX e)Minor change to the restricted part of an Active Substance Master File.IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediateProcedure type FORMCHECKBOX a)Up to 10-fold increase compared to the currently approved batch size  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Downscaling FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)The change requires assessment of the comparability of a biological/immunological active substance. II FORMCHECKBOX d)More than 10-fold increase compared to the currently approved batch size IB FORMCHECKBOX e)The scale for a biological/immunological active substance is increased / decreased without process change (e.g. duplication of line).IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substanceProcedure type FORMCHECKBOX a)Tightening of in-process limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new in-process test and limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a non-significant in-process test  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the active substance II FORMCHECKBOX e)Deletion of an in-process test which may have a significant effect on the overall quality of the active substance II FORMCHECKBOX f)Addition or replacement of an in-process test as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.a.5 Changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenzaProcedure type FORMCHECKBOX a)Replacement of the strain(s) in a seasonal, pre-pandemic or a pandemic vaccine against human influenza II B.I.b Change in control of the active substanceProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substanceProcedure type FORMCHECKBOX a)Tightening of specification limits for medicinal products subject to Official Batch Release FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX e)Deletion of a specification parameter which may have a significant effect on the overall quality of the active substance and/or the finished productII FORMCHECKBOX f)Change outside the approved specifications limits range for the active substanceII FORMCHECKBOX g)Widening of the approved specifications limits for starting materials/intermediates, which may have a significant effect on the overall quality of the active substance and/or the finished product II FORMCHECKBOX h)Addition or replacement (excluding biological or immunological substance) of a specification parameter as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substanceProcedure type FORMCHECKBOX a)Minor changes to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Deletion of a test procedure for the active substance or a starting material/reagent/ intermediate, if an alternative test procedure is already authorised. FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Change (replacement) to a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance. e.g. peptide map, glyco-map, etc.II FORMCHECKBOX e)Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediateIB9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.c Change in container closure system of the active substanceProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.I.c.1 Change in immediate packaging of the active substanceProcedure type FORMCHECKBOX a)Qualitative and/or quantitative composition FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological active substancesII FORMCHECKBOX c) Liquid active substances (non sterile)IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substanceProcedure type FORMCHECKBOX a)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Addition or replacement of a specification parameter as a result of a safety or quality issue IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.c.3 Change in test procedure for the immediate packaging of the active substanceProcedure type FORMCHECKBOX a)Minor changes to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Other changes to a test procedure (including replacement or addition) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a test procedure if an alternative test procedure is already authorised  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier.Procedure typea)Re-test period/storage period  FORMCHECKBOX 1.Reduction FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Extension of the retest period based on extrapolation of stability data not in accordance with ICH guidelines*II FORMCHECKBOX 3.Extension of storage period of a biological/ immunological active substance not in accordance with an approved stability protocol.II FORMCHECKBOX 4. Extension or introduction of a re-test period/storage period supported by real time dataIBb)Storage conditions  FORMCHECKBOX 1.Change to more restrictive storage conditions of the active substance FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Change in storage conditions of biological/ immunological active substances, when the stability studies have not been performed in accordance with a currently approved stability protocolII FORMCHECKBOX 3.Change in storage conditions of the active substanceIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.I.e.1 Introduction of a new design space or extension of an approved design space for the active substance, concerning:Procedure type FORMCHECKBOX a)One unit operation in the manufacturing process of the active substance including the resulting in-process controls and/or test procedures II FORMCHECKBOX b)Test procedures for starting materials/reagents/ intermediates and/or the active substanceII Procedure type FORMCHECKBOX B.I.e.2 Introduction of a post approval change management protocol related to the active substanceII Procedure type FORMCHECKBOX B.I.e.3 Deletion of an approved change management protocol related to the active substance FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.a Change in description and composition of the Finished ProductProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.II.a.1 Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking.Procedure type FORMCHECKBOX a)Changes in imprints, bossing or other markings FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Changes in scoring/break lines intended to divide into equal dosesIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.a.2 Change in the shape or dimensions of the pharmaceutical formProcedure type FORMCHECKBOX a)Immediate release tablets, capsules, suppositories and pessaries  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Gastro-resistant, modified or prolonged release pharmaceutical forms and scored tablets intended to be divided into equal dosesIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.a.3 Changes in the composition (excipients) of the finished productProcedure typea)Changes in components of the flavouring or colouring system FORMCHECKBOX 1.Addition , deletion or replacement  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Increase or reduction  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 3.Biological veterinary medicinal products for oral use for which the colouring or flavouring agent is important for the uptake by target animal species IIb)Other excipients FORMCHECKBOX 1.Any minor adjustment of the quantitative composition of the finished product with respect to excipients FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the medicinal product. II FORMCHECKBOX 3.Change that relates to a biological/immunological productII FORMCHECKBOX 4.Any new excipient that includes the use of materials of human or animal origin for which assessment is required of viral safety data or TSE risk. II FORMCHECKBOX 5.Change that is supported by a bioequivalence study.II FORMCHECKBOX 6.Replacement of a single excipient with a comparable excipient with the same functional characteristics and at a similar levelIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.a.4 Change in coating weight of oral dosage forms or change in weight of capsule shellsProcedure type FORMCHECKBOX a)Solid oral pharmaceutical forms FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Gastro-resistant, modified or prolonged release pharmaceutical forms where the coating is a critical factor for the release mechanism.II FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX B.II.a.5 Change in concentration of a single-dose, total use parenteral product, where the amount of active substance per unit dose (i.e. the strength) remains the same.II Procedure type FORMCHECKBOX B.II.a.6 Deletion of the solvent / diluent container from the packIB B.II.b Change in manufacture of the Finished ProductProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished productProcedure type FORMCHECKBOX a)Secondary packaging site FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Primary packaging site  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products.II FORMCHECKBOX d)Site which requires an initial or product specific inspectionII FORMCHECKBOX e)Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products.IB FORMCHECKBOX f)Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products manufactured using an aseptic method excluding biological/ immunological medicinal productsIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.b.2 Change to batch release arrangements and quality control testing of the finished productProcedure type FORMCHECKBOX a)Replacement or addition of a site where batch control/testing takes place FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: b)Replacement or addition of a manufacturer responsible for batch release FORMCHECKBOX 1.Not including batch control/testing FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Including batch control/testing FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 3.Including batch control/testing for a biological/immunol. product and one of the test methods performed at that site is a biological/immunol./immunochemical method.II9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.b.3 Change in the manufacturing process of the finished productProcedure type FORMCHECKBOX a)Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions. FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product II FORMCHECKBOX c)The product is a biological/immunological medicinal product and the change requires an assessment of comparability.II FORMCHECKBOX d)Introduction of a non-standard terminal sterilisation methodII FORMCHECKBOX e)Introduction or increase in the overage that is used for the active substanceII FORMCHECKBOX f)Minor change in the manufacturing process of an aqueous oral suspension.IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.b.4 Change in the batch size (including batch size ranges) of the finished productProcedure type FORMCHECKBOX a)Up to 10-fold compared to the currently approved batch size  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Downscaling down to 10-fold FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)The change requires assessment of the comparability of a biological/immunological medicinal product. II FORMCHECKBOX d)The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes II FORMCHECKBOX e)More than 10-fold increase compared to the currently approved batch size for immediate release IB FORMCHECKBOX f)The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line).IB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished productProcedure type FORMCHECKBOX a)Tightening of in-process limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new tests and limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a non-significant in-process test  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Deletion of an in-process test which may have a significant effect on the overall quality of the finished productII FORMCHECKBOX e)Widening of the approved IPC limits, which may have a significant effect on overall quality of the finished product II FORMCHECKBOX f)Addition or replacement of an in-process test as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.c Change in control of excipients in the Finished ProductProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.II.c.1 Change in the specification parameters and/or limits of an excipientProcedure type FORMCHECKBOX a)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Change outside the approved specifications limits rangeIIe)Deletion of a specification parameter which may have a significant effect on the overall quality of the finished productII FORMCHECKBOX f)Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.c.2 Change in test procedure for an excipientProcedure type FORMCHECKBOX a)Minor changes to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Deletion of a test procedure if an alternative test procedure is already authorised FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagentII FORMCHECKBOX d)Other changes to a test procedure (including replacement or addition) IB9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.c.3 Change in source of an excipient or reagent with TSE riskProcedure typea)From TSE risk material to vegetable or synthetic origin FORMCHECKBOX 1.For excipients or reagents not used in the manufacture of a biological / immunological active substance or in a biological / immunological medicinal product FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.For excipients or reagents used in the manufacture of a biological / immunological active substance or in a biological / immunological medicinal productIB FORMCHECKBOX b)Change or introduction of a TSE risk material or replacement of a TSE risk material from a different TSE risk material, not covered by a TSE certificate of suitabilityII9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.c.4 Change in synthesis or recovery of a non-pharmacopoeial excipient (when described in the dossier)Procedure type FORMCHECKBOX a)Minor change in synthesis or recovery of a non-pharmacopoeial excipient  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The specifications are affected or there is a change in physico-chemical properties of the excipient which may affect the quality of the finished product.II FORMCHECKBOX c)The excipient is a biological/immunological substance II FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.d Change in control of the Finished ProductProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.II.d.1 Change in the specification parameters and/or limits of the finished productProcedure type FORMCHECKBOX a)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Tightening of specification limits for medicinal products subject to Official Batch Release FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX e)Change outside the approved specifications limits rangeII FORMCHECKBOX f)Deletion of a specification parameter which may have a significant effect on the overall quality of the finished productII FORMCHECKBOX g)Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.d.2 Change in test procedure for the finished productProcedure type FORMCHECKBOX a)Minor changes to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Deletion of a test procedure if an alternative method is already authorised FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent. II FORMCHECKBOX d)Other changes to a test procedure (including replacement or addition) IB9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX B.II.d.3 Variations related to the introduction of real-time release or parametric release in the manufacture of the finished productII B.II.e Change in container closure system of the Finished ProductProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.II.e.1 Change in immediate packaging of the finished productProcedure typea) Qualitative and quantitative composition FORMCHECKBOX 1.Solid pharmaceutical forms FORMCHECKBOX  IA FORMCHECKBOX  IB9Implement. Date:  FORMCHECKBOX 2.Semi-solid and non-sterile liquid pharmaceutical formsIB FORMCHECKBOX 3.Sterile medicinal products and biological/ immunological medicinal products.II FORMCHECKBOX 4.The change relates to a less protective pack where there are associated changes in storage conditions and/or reduction in shelf life. IIb)Type of container FORMCHECKBOX 1.Solid, semi-solid and non-sterile liquid pharmaceutical formsIB FORMCHECKBOX 2.Sterile medicinal products and biological/ immunological medicinal productsII FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished productProcedure type FORMCHECKBOX a)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Addition or replacement of a specification parameter as a result of a safety or quality issueIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.3 Change in test procedure for the immediate packaging of the finished productProcedure type FORMCHECKBOX a)Minor changes to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Other changes to a test procedure (including replacement or addition) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a test procedure if an alternative test procedure is already authorised FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.4 Change in shape or dimensions of the container or closure (immediate packaging)Procedure type FORMCHECKBOX a)Non-sterile medicinal products FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The change in shape or dimensions concerns a fundamental part of the packaging material, which may have a significant impact on the delivery, use, safety or stability of the finished productII FORMCHECKBOX c)Sterile medicinal productsIB9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.5 Change in pack size of the finished productProcedure typea)Change in the number of units (e.g. tablets, ampoules, etc.) in a pack FORMCHECKBOX 1.Change within the range of the currently approved pack sizes FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Change outside the range of the currently approved pack sizesIB FORMCHECKBOX b)Deletion of a pack size(s) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, and biological/ immunological multidose parenteral medicinal products.II FORMCHECKBOX d)Change in the fill weight/fill volume of non-parenteral multi-dose (or single-dose, partial use) productsIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used))Procedure type FORMCHECKBOX a)Change that affects the product information FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Change that does not affect the product information FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier)Procedure type FORMCHECKBOX a)Deletion of a supplier FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Replacement or addition of a supplier FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Any change to suppliers of spacer devices for metered dose inhalers II9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.f.1 Change in the shelf-life or storage conditions of the finished productProcedure typea)Reduction of the shelf life of the finished product FORMCHECKBOX 1.As packaged for sale FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.After first opening FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 3.After dilution or reconstitution FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: b)Extension of the shelf life of the finished product FORMCHECKBOX 1.As packaged for sale (supported by real time data)IB FORMCHECKBOX 2.After first opening (supported by real time data)IB FORMCHECKBOX 3.After dilution or reconstitution (supported by real time data)IB FORMCHECKBOX 4.Extension of the shelf-life based on extrapolation of stability data not in accordance with ICH guidelines*II FORMCHECKBOX 5.Extension of storage period of a biological/ immunological medicinal product in accordance with an approved stability protocol.IB FORMCHECKBOX c)Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocolII FORMCHECKBOX d)Change in storage conditions of the finished product or the diluted/reconstituted productIB FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.II.g.1 Introduction of a new design space or extension of an approved design space for the finished product, excluding biologicals, concerning:Procedure type FORMCHECKBOX a)One or more unit operations in the manufacturing process of the finished product including the resulting in-process controls and/or test proceduresII FORMCHECKBOX b)Test procedures for excipients / intermediates and/or the finished product.II Procedure type FORMCHECKBOX B.II.g.2 Introduction of a post approval change management protocol related to the finished productII Procedure type FORMCHECKBOX B.II.g.3 Deletion of an approved change management protocol related to the finish product FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.III.1 Submission of a new or updated Ph. Eur. certificate of suitability: - For an active substance - For a starting material/reagent/intermediate used in the manufacturing process of the active substance - For an excipientProcedure typea)European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. FORMCHECKBOX 1.New certificate from an already approved manufacturer FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Updated certificate from an already approved manufacturer FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 3.New certificate from a new manufacturer (replacement or addition) FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: b)European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient FORMCHECKBOX 1.New certificate for an active substance from a new or an already approved manufacturer  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.New certificate for a starting material/reagent/ intermediate/or excipient from a new or an already approved manufacturer  FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 3.Updated certificate from an already approved manufacturer FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member StateProcedure typea)Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State FORMCHECKBOX 1.Active substance FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Excipient/active substance starting material FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur. FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.IV Change in Medical DevicesProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  B.IV.1 Change of a measuring or administration deviceProcedure typea)Addition or replacement of a device which is not an integrated part of the primary packaging FORMCHECKBOX 1.Device with CE marking  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX 2.Device without CE marking (for veterinary products only)IB FORMCHECKBOX 3.Spacer device for metered dose inhalersII FORMCHECKBOX b)Deletion of a device FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Addition or replacement of a device which is an integrated part of the primary packagingII9 If one of the conditions is not met and the change is not specifically listed as Type II. B.IV.2 Change in specification parameters and/or limits of a measuring or administration device for veterinary medicinal productsProcedure type FORMCHECKBOX a)Tightening of specification limits FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Addition of a new specification parameter to the specification with its corresponding test method FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Widening of the approved specifications limits, which has a significant effect on the overall quality of the device II FORMCHECKBOX d)Deletion of a specification parameter that has a significant effect on the overall quality of the deviceII FORMCHECKBOX e)Addition of a specification parameter as a result of a safety or quality issueIB FORMCHECKBOX f)Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.IV.3 Change in test procedure of a measuring or administration device for veterinary medicinal productsProcedure type FORMCHECKBOX a)Minor change to an approved test procedure FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Other changes to a test procedure (including replacement or addition) FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Deletion of a test procedure if an alternative test procedure is already authorised FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure)Procedure type FORMCHECKBOX a)First-time inclusion of a new Plasma Master File affecting the properties of the finished productII FORMCHECKBOX b)First-time inclusion of a new Plasma Master File not affecting the properties of the finished productIB FORMCHECKBOX c)Inclusion of an updated/amended Plasma Master File when changes affect the properties of the finished productIB FORMCHECKBOX d)Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.V.a.2 Inclusion of a new, updated or amended Vaccine Antigen Master File in the marketing authorisation dossier of a medicinal product. (VAMF 2nd step procedure)Procedure type FORMCHECKBOX a)First-time inclusion of a new Vaccine Antigen Master FileII FORMCHECKBOX b)Inclusion of an updated/amended Vaccine Antigen Master File, when changes affect the properties of the finished productIB & , . J L N P ɸpbMp< hn5:CJ OJQJmH sH )jwh)Y{CJOJQJUmH sH hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH h>:OJQJmH sH &h3h>5:CJOJQJmH sH  h>5:CJOJQJmH sH hn hn5:CJOJQJmH sH hn:CJOJQJmH sH #h%hnCJH*OJQJmH sH #hVh%P5CJOJQJ^JaJh8UP Qkd$$Ifl4A0["))44 laf4 $$Ifa$$a$$a$gd\$V^`Va$gd%P$$a$gd8U & r | ­Мs]J]7]7]%h}O5CJOJQJ^JaJmH sH %heO5CJOJQJ^JaJmH sH +hb?h%P5CJOJQJ^JaJmH sH )jh)Y{CJOJQJUmH sH hnCJOJQJaJmH sH hn hn5:CJ OJQJmH sH )jh)Y{CJOJQJUmH sH hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH hn5OJQJmH sH  hn5:CJOJQJmH sH  f b uuj[Ud$If^U d$If >Q'Zd11$If^Z Q'Zd11$If^Z$IfOkdc$$Ifl40["))44 laf4     d f h ־}d}Hd}2}d}+heOhtP5CJOJQJ^JaJmH sH 7j>hb?h)Y{CJOJQJU^JaJmH sH 1jhb?h)Y{CJOJQJU^JaJmH sH (hb?hnCJOJQJ^JaJmH sH +hb?hy5CJOJQJ^JaJmH sH +hb?hn5CJOJQJ^JaJmH sH .hb?hn5CJH*OJQJ^JaJmH sH +hb?h%P5CJOJQJ^JaJmH sH %h}O5CJOJQJ^JaJmH sH  * ʵ~pZD.+heOhtP5CJOJQJ^JaJmH sH +hn)shn5CJOJQJ^JaJmH sH +hn)sh`5CJOJQJ^JaJmH sH hnCJOJQJmH sH hnOJQJmH sH (hb?h%PCJOJQJ^JaJmH sH +hb?h%P5CJOJQJ^JaJmH sH (hb?hnCJOJQJ^JaJmH sH 1jhb?h)Y{CJOJQJU^JaJmH sH 7jhb?h)Y{CJOJQJU^JaJmH sH  * . < > @ D P V ` b d ӫvZ>7jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7j*hn)sh)Y{CJOJQJU^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH %hE5CJOJQJ^JaJmH sH +heOhtP5CJOJQJ^JaJmH sH +heOheO5CJOJQJ^JaJmH sH    " $ * , H J L R T p r t z | ѵљ}aE7jdhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jxhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH     !"01256D϶뚶~bF7jhn)sh)Y{CJOJQJU^JaJmH sH 7j<hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jPhn)sh)Y{CJOJQJU^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH DEFIJXYZ\]klmpqʵʵʵʵ}ʵʵaʵʵEʵʵ7j hn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7j( hn)sh)Y{CJOJQJU^JaJmH sH  ʵʵʵʵ}ʵʵaʵʵEʵʵ7jN hn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH 7jb hn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jv hn)sh)Y{CJOJQJU^JaJmH sH     !$%34589GHILM[\]abpʵʵʵʵ}ʵʵaʵʵEʵʵ7jhn)sh)Y{CJOJQJU^JaJmH sH 7j&hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7j:hn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7j hn)sh)Y{CJOJQJU^JaJmH sH pqrvw8:ʵʵʵʄhSA0 hn)shnCJOJQJ^JaJ#hn)shO5CJOJQJ^JaJ(h]Nh MyCJOJQJ^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)sh MyCJOJQJ^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH b :pH( /H F Ry (#%Ud$If^U+ /H F Ry (#%d$If]gd,b+, /H F Ry (#%Ud$If]^U $If]gdO* ,H b&u9!#&Ud$If]^U:<XZ\bdѵљ}aE7jLhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7j`hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jthn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH  "$*,HJLRTprtz|϶뚶~bF7jhn)sh)Y{CJOJQJU^JaJmH sH 7j$hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7j8hn)sh)Y{CJOJQJU^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH    !"01256DEFHIWʵʵʵʵ}ʵʵaʵʵEʵʵ7jhn)sh)Y{CJOJQJU^JaJmH sH 7jrhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH WXY\]klmpqʵʵʵʵ}ʵʵaʵʵEʵʵ7j6hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jJhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7j^hn)sh)Y{CJOJQJU^JaJmH sH    ʵʵʵʵ}ʵʵaʵʵEʵʵ7jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7j"hn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH  !$%34589GHIMN\]^bcqrsuʵʵʵʵ}ʵʵaʵʵEʵ7jhn)sh)Y{CJOJQJU^JaJmH sH 7j\hn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH 7jphn)sh)Y{CJOJQJU^JaJmH sH (hn)shnCJOJQJ^JaJmH sH 1jhn)sh)Y{CJOJQJU^JaJmH sH 7jhn)sh)Y{CJOJQJU^JaJmH sH uvѵ栋v`J4*hhhn56CJOJQJ^JmH sH *hhh56CJOJQJ^JmH sH +hn)shn5CJOJQJ^JaJmH sH +hn)sh5CJOJQJ^JaJmH sH (hn)sh,b+CJOJQJ^JaJmH sH (hn)shnCJOJQJ^JaJmH sH (hGhfCJOJQJ^JaJmH sH 7jHhGh)Y{CJOJQJU^JaJmH sH (hGhnCJOJQJ^JaJmH sH 1jhGh)Y{CJOJQJU^JaJmH sH  68:<>BHLNPlnprtx~õõsbõMõsõ)j4 h)Y{CJOJQJUmH sH  hn5CJH*OJQJmH sH hn5CJOJQJmH sH h$X5CJOJQJmH sH hz5CJOJQJmH sH )jh)Y{CJOJQJUmH sH hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH +hn)shn5CJOJQJ^JaJmH sH 'hzhz5CJOJQJ^JmH sH NJwM) 2H F Ry (#%Ud$If^U. 2H F Ry (#%d$If^gd,b+K$, 2H F Ry (#%d$If^gd,b+, 2H F Ry (#%d$If^gd&ʻueP?'P?/j!heOh)Y{CJOJQJUmH sH  heOh&CJOJQJmH sH )jheOh)Y{CJOJQJUmH sH heOhnH*OJQJmH sH heOh2EH*OJQJmH sH #heOh]N5CJOJQJmH sH #heOhn5CJOJQJmH sH #heOh$X5CJOJQJmH sH hz5CJOJQJmH sH hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH )j h)Y{CJOJQJUmH sH 68:<>BJLhjlnpt̺w`QQww:QQ,j!h)Y{5CJOJQJUmH sH h$X5CJOJQJmH sH ,jz!h)Y{5CJOJQJUmH sH hn5CJOJQJmH sH &jh)Y{5CJOJQJUmH sH h&h&H*OJQJmH sH heOh2EH*OJQJmH sH #heOh]N5CJOJQJmH sH #heOh&5CJOJQJmH sH #heOh$X5CJOJQJmH sH hz5CJOJQJmH sH t|ŶsdVD6hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH hgQCJOJQJmH sH h$X5CJOJQJmH sH 2jJ"h&h)Y{5CJOJQJUmH sH #h&hgQ5CJOJQJmH sH ,jh&h)Y{5CJOJQJUmH sH h,b+5CJOJQJmH sH h@NPRnprtvݶݧugVE1'hY*hY*5CJOJQJ^JmH sH !h5CJOJQJ^JmH sH !hz5CJOJQJ^JmH sH hZMCJOJQJmH sH )j&h)Y{CJOJQJUmH sH h_CJOJQJmH sH hY*5CJOJQJmH sH hz5CJOJQJmH sH )jT&h)Y{CJOJQJUmH sH #jh)Y{CJOJQJUmH sH hnCJOJQJmH sH 'hWshWs5CJOJQJ^JmH sH P`z$If<kd,($$Ifl4")))44 laf4 Sd$If^gd~P Sd$If^gdZM Sd$If^gd_^`b~Ʋ}kZE4 h~PhnCJOJQJmH$sH$)jh~Ph)Y{CJOJQJUmH$sH$ h~Ph~PCJOJQJmH$sH$#h~Ph~P5CJOJQJmH$sH$)j@'h)Y{CJOJQJUmH sH hyCJOJQJmH sH #jh)Y{CJOJQJUmH sH 'hY*hn5CJOJQJ^JmH sH 'hY*hY*5CJOJQJ^JmH sH 'hY*hz5CJOJQJ^JmH sH !hz5CJOJQJ^JmH sH  ~zjfWH9( hA8hnCJOJQJmH sH hn>*CJOJQJmH sH h/8/>*CJOJQJmH sH hnCJH*OJQJmH sH heOheOCJOJQJaJmH sH hnCJOJQJaJmH sH hnhn5CJOJQJmH sH #h~PhY*5CJOJQJmH$sH$#h~Phz5CJOJQJmH$sH$ h~PhnCJOJQJmH$sH$)jh~Ph)Y{CJOJQJUmH$sH$/j'h~Ph)Y{CJOJQJUmH$sH$, F$|kkZI ^`gddP ^`gdtk ^`gde<kd($$Ifl4")))44 laf4$If?kd{($$Ifl4")))44 laf4yteO 'xǶxiWE3#hc%hc%>*CJOJQJmH$sH$#hc%hn>*CJOJQJmH$sH$#hc%h/8/>*CJOJQJmH$sH$heCJH*OJQJmH sH heCJOJQJmH sH  hhnCJOJQJmH sH $h_hn0JCJOJQJmH sH h)Y{jh)Y{U h_hnCJOJQJmH sH "h4CJOJQJ^JaJmH sH "h]NCJOJQJ^JaJmH sH (h4h4CJOJQJ^JaJmH sH  "2rͼͫsbQIEIh)Y{jh)Y{U h3@hzCJOJQJmH sH  h3@hnCJOJQJmH sH hzCJOJQJmH sH hnCJOJQJmH sH h5CJOJQJmH sH h]NCJOJQJmH sH  hc%h2CJOJQJmH$sH$ hc%hzCJOJQJmH$sH$ hc%h5CJOJQJmH$sH$ hc%htkCJOJQJmH$sH$ hc%hc%CJOJQJmH$sH$$&(*,.^`   @ ~ ھq_M#hEh_CJH*OJQJmH sH #hEh2ECJH*OJQJmH sH  htkhtkCJOJQJmH sH hzCJOJQJmH sH h]NCJOJQJmH sH h:CJOJQJmH sH #h]Nhtk>*CJOJQJmH sH htkCJOJQJmH sH h,b+CJOJQJmH sH hnCJOJQJmH sH jh)Y{Uhn0JCJOJQJmH sH  !!"","""""""""""##&#F#H#### $$$$0$2$D$F$H$J$$$$$$$޼龎wވf hEh,b+CJOJQJmH sH  hEh=CJOJQJmH sH  hEh{CJOJQJmH sH #hEh2ECJH*OJQJmH sH  hEhZMCJOJQJmH sH  hEh4CJOJQJmH sH  hEhkCJOJQJmH sH  hEh]NCJOJQJmH sH  hEhCJOJQJmH sH (F$$%%%\&^&&&&&&&&& $If $If $Ifgd `  ^`gddP gd_$$$$%%%<%n%p%v%%%%%%%%%%%%&&ʹʗxi[J<hmCJOJQJ^JaJ h h `CJOJQJ^JaJhnCJOJQJmH sH h4CJH*OJQJmH sH h&CJOJQJmH sH  hEh5CJOJQJmH sH  hEhmCJOJQJmH sH  hEhSw\CJOJQJmH sH  hEhroBCJOJQJmH sH  hEhc:PCJOJQJmH sH #hEh&CJH*OJQJmH sH #hEh2ECJH*OJQJmH sH &V&X&Z&\&^&&&&&&&&&&&&&&&&&ijĞĞzeĞaO@h69CJH*OJQJmH sH #h+|huCJH*OJQJmH sH hn(h h`CJOJQJ^JaJmH sH "hSw\CJOJQJ^JaJmH sH "hmCJOJQJ^JaJmH sH (h h:A_CJOJQJ^JaJmH sH  h hnCJOJQJ^JaJ(h hnCJOJQJ^JaJmH sH +h huCJH*OJQJ^JaJmH sH  h h `CJOJQJ^JaJ&&^(*****+sss\ o#$If^gdE ^gdE gd$6 r^`rgd69bkd)$$Ifl4F ")h)    44 laf4&''4'L'P'R'h'''''&(Z(\(^(`(b(~((((((B)D)f)h))޾t_t_tNN hc%h?exCJOJQJmH$sH$(hc%hc%CJOJQJ^JaJmH$sH$(hc%h?exCJOJQJ^JaJmH$sH$(hc%h CJOJQJ^JaJmH$sH$hoCJOJQJmH$sH$#h+|huCJH*OJQJmH$sH$h+|CJH*OJQJmH$sH$ hc%hc%CJOJQJmH$sH$ hc%h CJOJQJmH$sH$ hc%h^8|CJOJQJmH$sH$))))))L*P*\***********п΅|m^O@O2h$6CJOJQJmH sH h$6CJH*OJQJmH sH h$65CJOJQJmH sH h5CJOJQJmH sH h. 5CJOJQJmH sH hE5CJOJQJmH sH #h+|h CJH*OJQJmH$sH$ hc%hiCJOJQJmH$sH$ hc%hmCJOJQJmH$sH$ hc%h CJOJQJmH$sH$ hc%hc%CJOJQJmH$sH$ hc%h?exCJOJQJmH$sH$h69CJOJQJmH$sH$*++8+:+`+d+p+r+++++++++++++++ŵ䐁seWI;h?(CJOJQJmH sH hle CJOJQJmH sH hN'CJOJQJmH sH hPCJOJQJmH sH h^e3CJOJQJmH sH hHY'CJH*OJQJmH sH #h.ehHY'CJH*OJQJmH sH $h1hHY'CJOJQJaJmH sH hYCJOJQJaJmH sH  hehHY'CJOJQJmH sH hYCJOJQJmH sH hHY'CJOJQJmH sH hCJOJQJmH sH +:+d+r+++++ $If#$If]^#gd @$If^gdE"$If^"gde++&kd)$$Ifl4֞ &/_7 ?  i ON0>44 laf4yt0zV+++++++,, , ,,,,,,,-<-P---------&.L.j.οsbsQsQsbQbQbsbs hEhle CJOJQJmH sH  hEhWiCJOJQJmH sH  hEh_&CJOJQJmH sH hmCJOJQJmH sH hNCJOJQJmH sH hle CJOJQJmH sH  h'&h_&CJOJQJmH sH houCJH*OJQJmH sH #h?(h_&CJH*OJQJmH sH hHY'CJOJQJmH sH hHY'CJOJQJmH sH hHY'++++++++$If^gdE o#$If^gdE++&kd*$$Ifl4֞ &/_7 ?  i ON0>44 laf4yt0zV+++,,,,,$If^gdE o#$If^gdE, ,,& ^`gdoukd+$$Ifl4֞ &/_7 ?  i ON0>44 laf4yt0zVj.n......../T/V////////60V0h00000пᮟ~m\N\NmNh^e3CJOJQJmH sH  hchcCJOJQJmH sH  hch_&CJOJQJmH sH hx'CJH*OJQJmH sH #h?(h_&CJH*OJQJmH sH houCJH*OJQJmH sH  hEh_&CJOJQJmH sH  hEhWiCJOJQJmH sH  hEhle CJOJQJmH sH  hEh_&CJOJQJmH sH houCJOJQJmH sH ,/1111133333r44 $$Ifa$gd^_|Y$If^Y`gd^e3 $ a$gdN h$ a$$ d]a$   r^`rgd?(^gdx' 0111D1L1X1~111111111111111ĵyyjXJhnCJOJQJmH sH #jh)Y{CJOJQJUmH sH hn6CJOJQJmH sH h^e35CJOJQJmH sH hq$5CJOJQJmH sH hn5CJOJQJmH sH h. 5CJOJQJmH sH hE5CJOJQJmH sH h$65CJOJQJmH sH h_&CJOJQJmH sH h^e3CJOJQJmH sH  h^e3h_&CJOJQJmH sH 111111112242622222223333333ʵ~p\H\&hvhh3T5:CJOJQJmH sH &hvhh}5:CJOJQJmH sH hq$CJOJQJmH sH h{puhnaJmH$sH$(h{puh{puCJOJQJ^JaJmH$sH$(h{puh^e3CJOJQJ^JaJmH$sH$(h{puhq$CJOJQJ^JaJmH$sH$hnCJOJQJmH sH #jh)Y{CJOJQJUmH sH )j,h)Y{CJOJQJUmH sH 3333(4`4p4r444444444so[K4[K-j-h)Y{CJOJQJU^JmH sH hEQCJOJQJ^JmH sH 'jh)Y{CJOJQJU^JmH sH hEQhEQ5CJOJQJ^Jhx5CJOJQJ^J!hEQ5CJOJQJ^JmH sH !h^e35CJOJQJ^JmH sH !hvh5CJOJQJ^JmH sH !hC9!5CJOJQJ^JmH sH !hEQ6CJOJQJaJmH sH hnCJOJQJmH sH hn5CJOJQJmH sH 444445zzzn $$Ifa$gd^_| $Ifgd^_|{kdC-$$Ifl0L L` t0 44 lalyt^_|4444445555"565J5\5`5x55555o[G3G[G[o'h{puh{pu6CJOJQJaJmH$sH$'h{puhvh6CJOJQJaJmH$sH$'h{puh^e36CJOJQJaJmH$sH$*h{puhvh56CJOJQJaJmH$sH$*h{puh^e356CJOJQJaJmH$sH$*h{puhEQ56CJOJQJaJmH$sH$hEQhxCJOJQJ^J$h/hEQCJOJQJ^JmH sH hxCJOJQJ^JmH sH h^e3CJOJQJ^JmH sH hEQCJOJQJ^J5577778]UIII@ $IfgdbQ $ a$gd!E$a$gdmwkdf.$$Ifl\L 7k` t0 44 lalyt^_|555506R6T6666667777 777l7ׯ{cKcK.hmwh5:CJOJQJ^JaJmH$sH$.hmwh~*5:CJOJQJ^JaJmH$sH$h. CJOJQJaJmH sH h!ECJOJQJaJmH sH 'h{puh{pu6CJOJQJaJmH$sH$'h{puhT-6CJOJQJaJmH$sH$'h{puh^e36CJOJQJaJmH$sH$'h{puhvh6CJOJQJaJmH$sH$'h{puhEQ6CJOJQJaJmH$sH$l7p777777777888Z8r8888>9X9n999ТxbxbxLxLx9L%hmw6CJOJQJ^JaJmH$sH$+hmwhf)6CJOJQJ^JaJmH$sH$+hmwhmw6CJOJQJ^JaJmH$sH$+hmwhbQ6CJOJQJ^JaJmH$sH$'hmwhbQ5CJOJQJ^JmH$sH$+hmwhbQ5CJOJQJ^JaJmH$sH$.hmwh{pu5:CJOJQJ^JaJmH$sH$.hmwh5:CJOJQJ^JaJmH$sH$.hmwhT-5:CJOJQJ^JaJmH$sH$899999999:4:pp$``$Ifa$gd&wgd!E<kd[/$$Ifl4(((44 lalf4 $Ifgd&w  o#$Ifgd&w g$Ifgd{pu g$IfgdbQ $$Ifa$gdmw 999999999: :::::$:(:*:,:.:0:2:4:6:L:\:^:b:ۻ۷ۦqqeQ&h, h ":CJH*OJQJmH sH h!EOJQJmH sH  h!E5:CJOJQJmH sH #hq2j5:CJH*OJQJmH sH #h!E5:CJH*OJQJmH sH  hJX5:CJOJQJmH sH h!E#h{puh!E5CJOJQJmH sH h{puCJOJQJmH sH h!ECJOJQJmH sH +hmwhbQ6CJOJQJ^JaJmH$sH$4:6:8:::<:>:@:B:D:F:H:J:L:N:P:R:T:V:X: $Ifgd&wRkd/$$Ifl409(9(44 lalf4yt "X:Z:\:^:; ="=@=B=D=ttk $Ifgd&w dh$Ifgd_ ^gd 5E e)^e`)gdT^gd69RkdI0$$Ifl409(9(44 lalf4yt " $Ifgd&w b:d::;;;;;;;;;< <<<><<<<<<==­tbךO$hmwhf)CJOJQJaJmH$sH$"hY1CJOJQJ^JaJmH$sH$"h69CJOJQJ^JaJmH$sH$&h, h ":CJH*OJQJmH$sH$$hmwh "CJOJQJaJmH$sH$(hmwhmwCJOJQJ^JaJmH$sH$(hmwhf)CJOJQJ^JaJmH$sH$(hmwh "CJOJQJ^JaJmH$sH$%hoCJH*OJQJ^JaJmH$sH$= ="=8=:=<=>=@=D=F=J=L=Z=r==ɶxhTA.A$hNhf)CJOJQJaJmH$sH$$hNh=CJOJQJaJmH$sH$'h69hoCJH*OJQJaJmH$sH$h, h=H*OJQJmH sH  h_h!Eh_h!EOJQJmH sH 'h_hq2jCJH*OJQJaJmH sH 'h_h!ECJH*OJQJaJmH sH $h_h!ECJOJQJaJmH sH 'hf)h|5CJOJQJaJmH sH h!ECJOJQJmH sH (hY1h "CJOJQJ^JaJmH$sH$D=F=|>~>>>???yysss o# $ a$gd!Egd!E e^e`gd69hkd0$$Ifl(( t0644 lalyt_=====&>(>|>~>>>>>>??? ?D?Ǹm^mJ6J'hmwhmw6CJOJQJ^JmH$sH$'hmwh ;6CJOJQJ^JmH$sH$hr`5OJQJ^JmH sH #hShn5OJQJ^JmH sH h5OJQJ^JmH sH h. CJOJQJmH sH h.CJOJQJmH sH hnCJOJQJmH sH hNh!EOJQJmH$sH$$hNh=CJOJQJaJmH$sH$$hNhf)CJOJQJaJmH$sH$$hNhNCJOJQJaJmH$sH$D?F?H?\?^?|???????@@@@뛊rZB)1jhSh)Y{CJOJQJU^JaJmH sH .hShn5:CJOJQJ^JaJmH sH .hSh5:CJOJQJ^JaJmH sH .hh5:CJOJQJ^JaJmH sH  hmwhnOJQJ^JmH$sH$'hmwhn6CJOJQJ^JmH$sH$'hmwh66CJOJQJ^JmH$sH$'hmwhu26CJOJQJ^JmH$sH$'hmwh ;6CJOJQJ^JmH$sH$'hmwh6CJOJQJ^JmH$sH$@@@@@@AAAAlAnApAAAAAAAAAAAAAA&B(B*BBByffP+hShn>*CJOJQJ^JaJmH sH %hu&>*CJOJQJ^JaJmH sH 0jhShnCJU^JaJmHnHsH u7je1hSh)Y{CJOJQJU^JaJmH sH "h_#CJOJQJ^JaJmH sH "h`CJOJQJ^JaJmH sH 1jhSh)Y{CJOJQJU^JaJmH sH (hShnCJOJQJ^JaJmH sH BBBBBBBBBB6C:CFCHCzC|CCCCCCCCDNDPDdD٤uccQ"hCJOJQJ^JaJmH sH "h`CJOJQJ^JaJmH sH +hShn5CJOJQJ^JaJmH sH 0jhShnCJU^JaJmHnHsH u7j1hSh)Y{CJOJQJU^JaJmH sH 1jhSh)Y{CJOJQJU^JaJmH sH (hShnCJOJQJ^JaJmH sH "hu&CJOJQJ^JaJmH sH dDfDhDrDtDDDDDDDD,#hhO6!5CJOJQJ^JaJ.hShn5:CJOJQJ^JaJmH sH .hh5:CJOJQJ^JaJmH sH "hCJOJQJ^JaJmH sH 7j2hSh)Y{CJOJQJU^JaJmH sH (hShnCJOJQJ^JaJmH sH 0jhShnCJU^JaJmHnHsH u1jhSh)Y{CJOJQJU^JaJmH sH 7jk2hSh)Y{CJOJQJU^JaJmH sH EEEEEEF F"F&F(FZF\FdFfFhFFFFFFƮ|g|Ug|g|Ug@(hO6!h$CJOJQJ^JaJmH sH "h$CJOJQJ^JaJmH sH (hShnCJOJQJ^JaJmH sH 1jhSh)Y{CJOJQJU^JaJmH sH 1hShn5CJOJQJ\]^JaJmH sH .hhq2j5CJH*OJQJ^JaJmH sH .hhS5CJH*OJQJ^JaJmH sH #hhO6!5CJOJQJ^JaJh65CJOJQJ^JaJ?$F\G`G KKKMNNXPQQsm]  ]` gd  o#gd $l?]l^`?a$ o#r^`rgdY1, o#e$d%d&d'dNOPQ`e( o#$d%d&d'dNOPQ FFFFFF4G6GJGLGNGXGZG^G`G믖eL:"hq2jCJOJQJ^JaJmH sH 0jhShnCJU^JaJmHnHsH u7jg3hSh)Y{CJOJQJU^JaJmH sH (hShnCJOJQJ^JaJmH sH 1jhSh)Y{CJOJQJU^JaJmH sH "hO6!CJOJQJ^JaJmH sH (hO6!hnCJOJQJ^JaJmH sH (hO6!h$CJOJQJ^JaJmH sH (hO6!hO6!CJOJQJ^JaJmH sH `GnG`HbHdHHHHHHHHHHHHHHII I ItIvIxIzIIиuu`u`H`u`. jhmwhnCJOJQJ^JaJmH$sH$(hmwh.(9CJOJQJ^JaJmH$sH$(hmwhu2CJOJQJ^JaJmH$sH$(hmwhnCJOJQJ^JaJmH$sH$1jhmwh)Y{CJOJQJU^JaJmH$sH$.hmwhn5CJOJQJ\^JaJmH$sH$.hmwh.(95CJOJQJ\^JaJmH$sH$.hmwhs?5CJOJQJ\^JaJmH$sH$IIIIIIIIIIIJJJJJJJJBJVJjJʱʜoʜSʱʜo>o(hmwhmwCJOJQJ^JaJmH$sH$7j[4hmwh)Y{CJOJQJU^JaJmH$sH$(hmwh.(9CJOJQJ^JaJmH$sH$. jhmwhnCJOJQJ^JaJmH$sH$(hmwhnCJOJQJ^JaJmH$sH$0jhmwhnCJU^JaJmHnHsH$u1jhmwh)Y{CJOJQJU^JaJmH$sH$7j3hmwh)Y{CJOJQJU^JaJmH$sH$jJlJpJrJtJJJJJJK KKKKL־֩t[E/E+hmwhCJOJQJ\^JaJmH$sH$+hmwhcCJOJQJ\^JaJmH$sH$0jhmwhnCJU^JaJmHnHsH$u7j4hmwh)Y{CJOJQJU^JaJmH$sH$1jhmwh)Y{CJOJQJU^JaJmH$sH$(hmwh.(9CJOJQJ^JaJmH$sH$. jhmwhnCJOJQJ^JaJmH$sH$(hmwhnCJOJQJ^JaJmH$sH$(hmwhu2CJOJQJ^JaJmH$sH$LbLdLLLLLLLLLM$M&M*M2M4M6M:M躥wbwbMb8Mb(hmwhmwCJOJQJ^JaJmH$sH$(hmwh(CJOJQJ^JaJmH$sH$(hmwh ;CJOJQJ^JaJmH$sH$(hmwhs?CJOJQJ^JaJmH$sH$1jhmwh)Y{CJOJQJU^JaJmH$sH$(hmwhnCJOJQJ^JaJmH$sH$+hmwhn6CJOJQJ^JaJmH$sH$.hmwhu26CJOJQJ\^JaJmH$sH$.hmwhc6CJOJQJ\^JaJmH$sH$:M>M@MBMtMvM|M~MMMMMMMMMMMMMٖvbO="h(vCJOJQJ^JaJmH sH %hkCJH*OJQJ^JaJmH sH 'h0 hq2jCJH*OJQJ^JmH sH hmwhnmH$sH$(hmwh(CJOJQJ^JaJmH$sH$(hmwh ;CJOJQJ^JaJmH$sH$(hmwhs?CJOJQJ^JaJmH$sH$1jhmwh)Y{CJOJQJU^JaJmH$sH$(hmwhnCJOJQJ^JaJmH$sH$"hRCJOJQJ^JaJmH$sH$MNNNNN N NNNNNN N"N#NpNqNNNNNvnjnSnvFhn5OJQJmH sH ,hq2jhq2j0JCJOJQJ^JaJmH sH h)Y{jh)Y{U(hq2jhq2jCJOJQJ^JaJmH sH "hCCJOJQJ^JaJmH sH "h(CJOJQJ^JaJmH sH "hu2CJOJQJ^JaJmH sH (h0 hmwCJOJQJ^JaJmH sH (h0 h(CJOJQJ^JaJmH sH (h0 hY1CJOJQJ^JaJmH sH NNNNNNOOOO'O)O-OQտթՓՓՓ{eeտN,hHhH0JCJOJQJ^JaJmH$sH$+hHh;k6CJOJQJ^JaJmH$sH$.hHhwRg6CJH*OJQJ^JaJmH$sH$+hHhM6CJOJQJ^JaJmH$sH$+hHhH6CJOJQJ^JaJmH$sH$+hHhwRg6CJOJQJ^JaJmH$sH$+hHh 6CJOJQJ^JaJmH$sH$(hHh CJOJQJ^JaJmH$sH$>Q@QLQbQdQfQlQrQQQQQQQQQQQѻѡmmS>(hHhnCJOJQJ^JaJmH sH 3hHhwRg6CJOJQJ^JaJmH$nH sH$tH 3hHhM6CJOJQJ^JaJmH$nH sH$tH 3hHhx-6CJOJQJ^JaJmH$nH sH$tH 3hHh 6CJOJQJ^JaJmH$nH sH$tH +hHhM6CJOJQJ^JaJmH$sH$+hHh 6CJOJQJ^JaJmH$sH$/hHhH0J6CJOJQJ^JaJmH$sH$QQ$R&R(R,R.RRRRRvSSSS TѿiQi9i9i.hHho6CJOJQJ]^JaJmH$sH$.hHhH6CJOJQJ]^JaJmH$sH$.hHhQd6CJOJQJ]^JaJmH$sH$.hhn5:CJOJQJ^JaJmH sH )hW#hQd5:CJOJQJ\^JaJ hW#hQdCJOJQJ^JaJ#hW#hQd5CJOJQJ^JaJ(hhnCJOJQJ^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH  TTTTDTFTLTTTTUUU8ULUNUUUUUUU VѸ}d}d}VE}d}d} hHPhwRgCJOJQJ^JaJhwRgCJOJQJ^JaJ1jhHPh)Y{CJOJQJU^JaJmH sH (hHPhnCJOJQJ^JaJmH sH  hHPhHPCJOJQJ^JaJ(hhnCJOJQJ^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH .hHhn5:CJOJQJ^JaJmH$sH$+hHhn6CJOJQJ^JaJmH$sH$ VV|VVVVVVVVVVhWWWWWWWW Xᬗ~~lZlZlZHl6"h?CJOJQJ^JaJmH sH "hLCJOJQJ^JaJmH sH "hCJOJQJ^JaJmH sH "h'< CJOJQJ^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH +hhn6CJOJQJ^JaJmH sH  hHPhwRgCJOJQJ^JaJhwRgCJOJQJ^JaJ hHPhHPCJOJQJ^JaJhmCJOJQJ^JaJQVW2X4XXXYYZZ[[[q+ o#$d%d&d'dNOPQgdS2q$d%d&d'dNOPQ]q^`gd'< /q$d%d&d'dNOPQ]q^` X"X$X&X.X4X6XhXjXlXXXXXYYYY$YrYٯiWBW)huNhuN5:CJOJQJ\^JaJ#huN5:CJOJQJ\^JaJ.hhn5:CJOJQJ^JaJmH sH )hW#hW#5:CJOJQJ\^JaJ1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH (hhCJOJQJ^JaJmH sH (hhnCJOJQJ^JaJmH sH "hCJOJQJ^JaJmH sH rYvYxYYYYYYYYYYY8ZZZ̺tt_L7)hhya5:CJOJQJ\^JaJ%hhya5:OJQJ\^JaJ)huNhya5:CJOJQJ\^JaJ1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH .hhn5:CJOJQJ^JaJmH sH #hya5:CJOJQJ\^JaJ#huN5:CJOJQJ\^JaJ#huNhuN5CJOJQJ^JaJhuN5CJOJQJ^JaJZZZZZZZZZ[[:[B[t[z[[[[[[[[[êêØnVnVnVnVnV>.hSohSo5:CJOJQJ^JaJmH sH .hhn5:CJOJQJ^JaJmH sH (h=U5:CJOJQJ^JaJmH sH )huNh=U5:CJOJQJ\^JaJ#h=U5:CJOJQJ\^JaJ1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH %hhya5:OJQJ\^JaJ(hhnCJOJQJ^JaJmH sH [[[\\ \&\6\:\Z\b\d\h\p\r\t\\\\\\\] ]8]:]<]>]p]r]t]]]]]]]]]ϺϺϺϺ{ϺϺb1jhh)Y{CJOJQJU^JaJmH sH h1ECJOJQJ^JaJ"hSoCJOJQJ^JaJmH sH hCJOJQJ^JaJ hSohSoCJOJQJ^JaJ(hSohnCJOJQJ^JaJmH sH 1jhSoh)Y{CJOJQJU^JaJmH sH .hSohn5:CJOJQJ^JaJmH sH &]^^^ ^"^$^2^6^8^N^Z^n^v^^^^^^϶taNNNt9)h3_h3_5:CJOJQJ\^JaJ%h6CJOJQJ^JaJmH sH %h3_6CJOJQJ^JaJmH sH +hhn6CJOJQJ^JaJmH sH %h `6CJOJQJ^JaJmH sH 0jhhnCJU^JaJmHnHsH u1jhh)Y{CJOJQJU^JaJmH sH 7jc5hh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH ^^____ _R_T_Z_\_^________*`,`.`r`t`v````}}ll}P7j5h3_h)Y{CJOJQJU^JaJmH sH  h3_h3_CJOJQJ^JaJ(h3_h3_CJOJQJ^JaJmH sH (h3_hnCJOJQJ^JaJmH sH 1jh3_h)Y{CJOJQJU^JaJmH sH .h3_hn5:CJOJQJ^JaJmH sH )h3_h3_5:CJOJQJ\^JaJ#h5:CJOJQJ\^JaJ````````&a*a,a@aBaDaNaPaRaTabbbbbιιιιιvbQb@b hXP6CJOJQJ]^JaJ hm6CJOJQJ]^JaJ&h3_h3_6CJOJQJ]^JaJ+h3_hn6CJOJQJ^JaJmH sH 7jW6h3_h)Y{CJOJQJU^JaJmH sH  h3_h3_CJOJQJ^JaJ(h3_hnCJOJQJ^JaJmH sH 1jh3_h)Y{CJOJQJU^JaJmH sH 0jh3_hnCJU^JaJmHnHsH u[blcnc@eBeef fv ]` o#$l?]l^`?a$$e^e`a$gdT+ o#$d%d&d'dNOPQgdS- o#x$d%d&d'dNOPQgdSbbbbbbb`cjclcncrctccллubN>)(h(Nh(NCJOJQJ^JaJmH$sH$hwCJOJQJ^JmH$sH$'hY1h(NCJH*OJQJ^JmH$sH$$hShnCJOJQJ^JmH sH (hhnCJOJQJ^JaJmH sH (hhCJOJQJ^JaJmH sH 7j6hh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH +hhn6CJOJQJ^JaJmH sH  cccdddd>e@eDefeleneeeeeeeeٵٟn\Jn8J8Jn#h hV5OJQJ^JmH$sH$#h h?5OJQJ^JmH$sH$#h h 5OJQJ^JmH$sH$#h hn5OJQJ^JmH$sH$#h h"\<5OJQJ^JmH$sH$hS5OJQJmH sH +h(NhS5CJOJQJ^JaJmH sH "h(NCJOJQJ^JaJmH$sH$"hXPCJOJQJ^JaJmH$sH$(h(Nh(NCJOJQJ^JaJmH$sH$"h CJOJQJ^JaJmH$sH$eeeeeef ffff,f>fBftfxffffﯗjQ81jh h)Y{CJOJQJU^JaJmH$sH$1h hn5:>*CJOJQJ^JaJmH$sH$(h/5:CJOJQJ^JaJmH$sH$.h hXP5:CJOJQJ^JaJmH$sH$.h h 5:CJOJQJ^JaJmH$sH$.h hVR5:CJOJQJ^JaJmH$sH$'h hXP6CJOJQJ^JmH$sH$'h h"\<6CJOJQJ^JmH$sH$ h hnOJQJ^JmH$sH$fffffff&g(g*g,g0g:glgtgggghhhhhhhhhiii뽨~iS+h hV6CJOJQJ^JaJmH$sH$(h h.3CJOJQJ^JaJmH$sH$(h heCJOJQJ^JaJmH$sH$(h hXPCJOJQJ^JaJmH$sH$(h h!CJOJQJ^JaJmH$sH$(h hP>CJOJQJ^JaJmH$sH$1jh h)Y{CJOJQJU^JaJmH$sH$(h hnCJOJQJ^JaJmH$sH$ fijjjj~kkkl@mmmnnn$ &^a$gdB/ V7$8$H$^`V $ &a$gdLgd#9 o#'q$d%d&d'dNOPQ]qiiiiii*j4j6jDjFjHjJjXj^jpj~jjjjjjfkhkzk~kӽӽөq`RA`q hh)CJOJQJ^JaJh)CJOJQJ^JaJ hh#9CJOJQJ^JaJ(hh#9CJOJQJ^JaJmH sH (hhnCJOJQJ^JaJmH sH hnCJOJQJmH sH 'h hn6CJOJQJ^JmH$sH$+h hV6CJOJQJ^JaJmH$sH$+h hn6CJOJQJ^JaJmH$sH$+h hXP6CJOJQJ^JaJmH$sH$~kkkkkkkkkkllllllllҽҽҽcҽNm@mBm^m`mbmdmεΙ΄r]εA7j8hh)Y{CJOJQJU^JaJmH sH (hh)CJOJQJ^JaJmH sH "h)CJOJQJ^JaJmH sH (hhkCJOJQJ^JaJmH sH 7j38hh)Y{CJOJQJU^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH 7hh#9CJH*OJPJQJ^JaJmH nHsH tHdmmmmmmmmmmmmmmmnnnn nֽ֡֌vֽZvI7#hY1hmLbCJH*OJQJmH sH !hB/CJH*OJQJaJmH sH 7j9hh)Y{CJOJQJU^JaJmH sH +hhB/CJH*OJQJ^JaJmH sH (hhaCJOJQJ^JaJmH sH 7j9hh)Y{CJOJQJU^JaJmH sH 1jhh)Y{CJOJQJU^JaJmH sH (hhnCJOJQJ^JaJmH sH (hhZCJOJQJ^JaJmH sH  n n nn1n?n@nInJnKnWnjnknlnmnonpnqntnvnnnnnnnnnnudThCJOJQJaJmH sH !hY1CJH*OJQJaJmH sH #hY1hmLbCJH*OJQJmH sH $hhmLbCJOJQJaJmH sH $hh?CJOJQJaJmH sH $hhmLbCJOJQJaJmH sH h?CJOJQJaJmH sH hmLbCJOJQJaJmH sH hY1CJOJQJaJmH sH hoCJH*OJQJmH sH nmnnnnnn>o6p8p:pq8rrTsv$ &$Ifa$gdr$ $If^`a$gdr$ &$Ifa$gdr$ &$Ifa$ $Ifgd7$If$ &^a$gdmLbnnnnnnnoo>opp6p8ppZpƱycyN5N1jh3@h)Y{CJOJQJU^JaJmH sH (h3@hrCJOJQJ^JaJmH sH +h3@h6CJOJQJ^JaJmH sH +h3@h76CJOJQJ^JaJmH sH  h3@hCJOJQJ^JaJ h3@h7CJOJQJ^JaJ(h3@hnCJOJQJ^JaJmH sH +h3@hn5CJOJQJ^JaJmH sH +h3@h75CJOJQJ^JaJmH sH hnCJOJQJmH sH Zp\p^pppppppp@qPqTqdqtqqqqqqqqqʵvvvvʵZʵI h3@hrCJOJQJ^JaJ7j:h3@h)Y{CJOJQJU^JaJmH sH (h3@h$$Ifl4((0(44 lalf4$Ifckd=$$Ifl4((0(44 lalf4xxxxxxxyyyyyyyhylypyȵ|k]L:L#hMWhMWCJH*OJQJ^JaJ hV{ht~CJOJQJ^JaJhnCJOJQJmH sH  h hnCJOJQJmH$sH$$h h. CJOJQJaJmH$sH$$h h CJOJQJaJmH$sH$$h hb0}CJOJQJaJmH$sH$$h h CJOJQJaJmH$sH$hoCJH*OJQJmH sH #hoh. CJH*OJQJmH sH hn$h. hnCJOJQJaJmH sH yyyyyyzzzzzzzv $$Ifa$hkd>$$Ifl4\((0(44 lalf4ytO$If 8$If$a$ pyyyyy zzz@zDzFzHzJzzzzzzzzƵƤƤrnXB+hV{hnCJH*OJQJ^JaJmH sH +hV{h-;5CJOJQJ^JaJmH sH hn hV{hnCJOJQJ^JaJh`FCJH*OJQJ^JaJ#hMWhMWCJH*OJQJ^JaJ hV{ht~CJOJQJ^JaJ hV{h`FCJOJQJ^JaJh`FCJOJQJ^JaJ(hV{hnCJOJQJ^JaJmH sH +hV{hn6CJOJQJ^JaJmH sH zzzzzB{D{`{b{d{f{{{ |r|x|Űŗ{fQfػɛػػylh`Ol@h5 5CJOJQJ\^J!h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j Mh5 OJQJU^JmH sH h5 6OJQJ^J)jLh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j Lh5 OJQJU^JmH sH *+,)kdM$$Iflr '7&8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a,-.=>PTcZMM xx$Ifgd`a $Ifgd`aykdN$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a>$If^>`gd`agd5 >?MNOPSTŠÊŊƊNJ۷ۦۏ~r[J=h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jPPh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH -jOh5 CJOJQJU^JmH sH !h5 5CJOJQJ^JmH sH h5 5CJOJQJ^J-jdOh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH NJ؊يڊ$kdP$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`aNJ؊يڊ܊567rȋñvbR;bbR-jRh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J'h/h5 5CJOJQJ^JmH sH h5 mH sH h5 0JOJQJ^JmH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 CJOJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jڊ67rϋkykdQ$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`agd5 ȋɋʋ̋΋ϋЋދߋ/ijĐreU>ԧ-jAUh5 CJOJQJU^JmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jSh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j&Sh5 CJOJQJU^JmH sH  /9000 $Ifgd`akdT$$IflֈL| '7k008 t0'4 lalyt`a/23OJJA5 $$Ifa$gd`a $Ifgd`agd5 kdU$$Ifl\L 7k` t0'84 lalyt`a$$If^a$gd`a/235݌ŵ}iYBi66h5 CJOJQJ^J-jWh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J'h/h5 5CJOJQJ^JmH sH h5 mH sH h5 0JOJQJ^JmH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ^Jh5 6OJQJ^Jތ ||qee|| $$Ifa$gd`a <$Ifgd`a $Ifgd`aykdV$$Ifl0L L` t0'84 lalyt`a݌ތߌ ̵̤́pcVF3%h5 CJH*OJQJ^JaJmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jwXh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH -jXh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH xy94+^gd5 gd5 kdX$$IflCֈL| '7k008 t0'4 lalyt`awxyz j^^J=2h5 6OJQJ^Jh5 56OJQJ^J&h/h5 56OJQJ^JmH sH h5 CJOJQJ^J-j[h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH h5 0JOJQJ^JmH sH "h5 CJOJQJ^JaJmH sH yz$5h__R_ $If^gd`a $Ifgd`aykd*Z$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a>$If^>`gd`a  "#$5679ĸġĐvfSA1h5 0JOJQJ^JmH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j[h5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jw[h5 CJOJQJU^JmH sH 5670+gd5 kdU\$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`a'*Uk_VVV $Ifgd`aykd]$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a>$If^>`gd`a^gd5 $%&*UVd義yiRyF3yi$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jM^h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH defhjklz{|~ijĐreU>ԧ-j`h5 CJOJQJU^JmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j9_h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j^h5 CJOJQJU^JmH sH 0kd_$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`aǐܐ $$Ifa$gd`a $Ifgd`aÐĐƐǐȐ֐אؐڐېܐKLM\ĸġĐvcQI4v)h5 5CJOJQJ^JmH nH sH tH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jah5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jTah5 CJOJQJU^JmH sH KLM900' $Ifgd`a^gd5 kd2b$$IflֈL| '7k008 t0'4 lalyt`aM\]osϑБyppcpp $If^gd`a $Ifgd`aykdac$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a \]^lmnorsͶݪjͪSB!h5 CJH*OJQJ^JmH sH -jeh5 CJOJQJU^JmH sH -jdh5 CJOJQJU^JmH sH h5 6OJQJ^J h5 56OJQJ^JmH sH h5 5CJOJQJ^Jh5 CJOJQJ^J-j8dh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^JϑБёӑ-./>?@NOPQTUɶyeU>e-jgh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J'h/h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 CJOJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^JБё-.900^gd5 kde$$Ifl{ֈL| '7k008 t0'4 lalyt`a./>?QUxh__R_ $If^gd`a $Ifgd`aykdf$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a>$If^>`gd`a Uwxyƶƶƶ|ƶk^QAh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j~hh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jhh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH &h/h5 56OJQJ^JmH sH 0+gd5 kdh$$IflbֈL| '7k008 t0'4 lalyt`a $Ifgd`aDSTUcdefxyzɼpdTB4h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jjh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH DSTfiy͔neeUH $If^gd`a$$If^a$gd`a $Ifgd`aykd1j$$Ifl0  t0'84 lalyt`a $$Ifa$gd`a <$Ifgd`aĔŔƔǔ͔ޔߔػػɆػqػdWSKh5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jlh5 OJQJU^JmH sH h5 6OJQJ^J)j@lh5 OJQJU^JmH sH )jkh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jTkh5 OJQJU^JmH sH ͔ޔߔ61gd5 kd,m$$Iflr '7&8 t0'4 lalyt`a $If^gd`a $Ifgd`a./0>?@D–j^K4-jvoh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-joh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH ./ADŖږh_____ $Ifgd`aykdEn$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`a –ĖŖƖԖՖ֖ٖؖږZ]ξξ|lξUB7h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH -jqh5 CJOJQJU^JmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -joh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH Z9000 $Ifgd`akdbp$$IflֈL| '7k008 t0'4 lalyt`aZ]^ps˘ΘOFFF $Ifgd`akdr$$Ifl\L 7k` t0'84 lalyt`a$$If^a$gd`a]^_mnos˘ΘϘИޘߘFIJKYZ[_һ⯜o⯜X⯜-juh5 CJOJQJU^JmH sH -juth5 CJOJQJU^JmH sH h5 OJQJ\^Jh5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j sh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^JΘϘFI_VVVF$$If^a$gd`a $Ifgd`akdrs$$IflT\L 7k` t0'84 lalyt`aIJ\__VVVF$$If^a$gd`a $Ifgd`akdt$$Ifl\L 7k` t0'84 lalyt`aԚ_VVVJJVV $$Ifa$gd`a $Ifgd`akddv$$Ifl\L 7k` t0'84 lalyt`aΚϚКҚӚԚĸĎĸwfYL<h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jExh5 CJOJQJU^JmH sH -jwh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jgwh5 CJOJQJU^JmH sH  900% <$Ifgd`a $Ifgd`akdx$$IflֈL| '7k008 t0'4 lalyt`a  !/0145CDEGHIWĸĦt_tJt?h5 6OJQJ^J)j>{h5 OJQJU^JmH sH )jzh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jRzh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jyh5 CJOJQJU^JmH sH  H`qr $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`aWXYZ`qrsuϛЛ$%&4ʽ|t`Q=-h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J'h/h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 h5 5CJOJQJ^Jh5 56OJQJ^Jh5 OJQJ^JmH sH #jh5 OJQJU^JmH sH )j{h5 OJQJU^JmH sH rsϛЛLGG6Y$If^Y`gd`agd5 kd*|$$IflrL '7k`8 t0'4 lalyt`a$%7:|yppppp $Ifgd`aykdC}$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a 456:|}ȵԥԥԥwԥfYL<h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j~h5 CJOJQJU^JmH sH -jt~h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j}h5 CJOJQJU^JmH sH ʜ͜v9000 $Ifgd`akdR$$IfltֈL| '7k008 t0'4 lalyt`aǜȜɜ͜vyz{cfghvwx|'й୚y୚nW୚-jeh5 CJOJQJU^JmH sH h5 OJQJ\^J-jh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^JvyzcfOFFF $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a$$If^a$gd`afgy|_VVVF$$If^a$gd`a $Ifgd`akdb$$IflT\L 7k` t0'84 lalyt`a*-ux_VVVF$$If^a$gd`a $Ifgd`akdۃ$$Ifl\L 7k` t0'84 lalyt`a'()-uxyzȵԐyԐȐgYDg5gYh5 6OJQJ^JmH sH )j͆h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jWh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^Jh5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jބh5 CJOJQJU^JmH sH xyڟ_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akdT$$Ifl\L 7k` t0'84 lalyt`aŸßƟǟ՟֟ןٟڟ۟acػɛػػylhUC8h/h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j/h5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jCh5 OJQJU^JmH sH ڟ)kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`aacàҠӠ.BZQQQQ $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`agd5 ^gd5 cdàҠӠԠ./=>?ABCQRSUȴnW@-jWh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jyh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J'h/h5 5CJOJQJ^JmH sH h5 mH sH UVWhijkyz{ơǡȡĹ~r[rDԹ-jڍh5 CJOJQJU^JmH sH -jrh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH BWhij|0kd͋$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`a|šơ $Ifgd`aơǡ١ܡA9000 $Ifgd`akdP$$IflPֈL| '7k008 t0'4 lalyt`aȡ֡סءܡADEFTUVZCFGHVŹyŹoXŹo-jch5 CJOJQJU^JmH sH h5 OJQJ^J-jh5 CJOJQJU^JmH sH h5 OJQJ\^Jh5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH ADEWZVMMM $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a $Ifgd`aCF_VVVM $Ifgd`a $Ifgd`akd`$$Ifl\L 7k` t0'84 lalyt`aFGY\lѣ_VVK>>V $If^gd`a <$Ifgd`a $Ifgd`akdْ$$Ifl\L 7k` t0'84 lalyt`aVWXYklm{|}ĸĦt_tJt?h5 6OJQJ^J)j>h5 OJQJU^JmH sH )jȔh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jRh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jܓh5 CJOJQJU^JmH sH ѣңӣգ/01234568ʽ|tcOcOcOc:)h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 h5 5CJOJQJ^Jh5 56OJQJ^Jh5 OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH ѣңӣ/0?::gd5 kd*$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a0٤h_______ $Ifgd`aykdC$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`a ٤ڤͶݪ̀ͪiXK>h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jܘh5 CJOJQJU^JmH sH -jth5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J$%&*WXfghjklz{|~ўt]L?h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j_h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH '*Wk90000 $Ifgd`akdR$$IflֈL| '7k008 t0'4 lalyt`ak0kd՛$$Ifl\ֈL| '7k008 t0'4 lalyt`a $Ifgd`aץإ"ìӠvà_NAh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jԝh5 CJOJQJU^JmH sH -jlh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jץ $Ifgd`a%(9000 $Ifgd`akdJ$$Ifl*ֈL| '7k008 t0'4 lalyt`a"#$(¦Ʀ9<=>LMNORѧҧȵԐyȵԐbԐȵԐKԐȐ-jh5 CJOJQJU^JmH sH -jkh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^Jh5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jyh5 CJOJQJU^JmH sH æƦ9<VMMM $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $Ifgd`a<=OR_VVVM $Ifgd`a $Ifgd`akdh$$Ifl\L 7k` t0'84 lalyt`a§ҧ&7_VVK>>V $If^gd`a <$Ifgd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`aҧӧ  &789ߦߑqdWSh5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jFh5 OJQJU^JmH sH )jФh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jZh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH 789?66^gd5 kd2$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a9;%&'+|hXAh5h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH (+h___V $Ifgd`a $Ifgd`aykdK$$Ifl0L L` t0 4 lalyt`a $$Ifa$gd`a$If^`gd`a+̩۩ܩݩѼzczWG5#jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j,h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH h5 h5 mH sH h5 5mH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH ̩۩_VQF: $$Ifa$gd`a <$Ifgd`agd5 ^gd5 kd|$$Ifl\L 7k` t0 4 lalyt`a۩ܩ=Ufg||qaT|G $If^gd`a $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykd$$Ifl0  t0'84 lalyt`a$%&)*89:<=>LMNOUfghi˼˼˼reXTLh5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH ghi#2LC2& $$Ifa$gd`aY$If^Y`gd`a^gd5 kdz$$Iflr '7&8 t0'4 lalyt`aijklmno#234BCDH;wdM?ABCUVWefgkͬάܬݬެijvԍcLč-jʳh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH -jbh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH UVhkͬ9000 $Ifgd`akd3$$IflֈL| '7k008 t0'4 lalyt`aͬ $Ifgd`a $$Ifa$gd`a }~ijvԍcLč-jMh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH -j׵h5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j2h5 CJOJQJU^JmH sH  }9000 $Ifgd`akd$$IflLֈL| '7k008 t0'4 lalyt`a} $Ifgd`a $$Ifa$gd`aȭɭʭέcfghvwxy|ͮЮijvԍcYBčc-jӹh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH -jZh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH ˭έc9000 $Ifgd`akd+$$Ifl~ֈL| '7k008 t0'4 lalyt`acfgy|ͮЮSJJJ $Ifgd`akdи$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`aЮѮ_VVVJ $$Ifa$gd`a $Ifgd`akdI$$Ifl\L 7k` t0'84 lalyt`aЮѮҮįTWXYghij|}~йЭyЭbЭP#jh5 OJQJU^JmH sH -j>h5 CJOJQJU^JmH sH -jżh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jLh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^JįTW_VVVJ $$Ifa$gd`a $Ifgd`akd»$$Ifl\L 7k` t0'84 lalyt`aWXjm}_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd;$$Ifl\L 7k` t0'84 lalyt`a~Ȱɰʰ˰Ѱ˼˼˼reXTA%h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH )j*h5 OJQJU^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH Ѱ)kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a?ABCDEFGIڱ۱լ{gW@g4h5 CJOJQJ^J-j`h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH @A۱,@ZQQQ $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`agd5 ^gd5 ,-;<=?@AOPQSTUfghiwɲɦɏ~qdTIh5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j>h5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH @Ufgh$kd$$Ifl.ֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`awxy}()*,-.<=>@ABSTȵԥԥԥwԥfYL<h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jYh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH hz}-BST $$Ifa$gd`a $Ifgd`aTUgj9000 $Ifgd`akd7$$IflֈL| '7k008 t0'4 lalyt`aTUVdefj'()+,-;<=?@ARй୚ЃЭl[NAh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j6h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jfh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^J,ARS $Ifgd`a $$Ifa$gd`aRSTUcdei%()*89:>ĵŵǵ #ўjўWE=h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH -jTh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH STfi%9000 $Ifgd`akd$$IflֈL| '7k008 t0'4 lalyt`a%();>ĵSJJJ $Ifgd`akdQ$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`aĵŵ!#ds_VQ>2 $$Ifa$gd`a5<$If^`5gd`agd5 ^gd5 kd$$Ifl\L 7k` t0'84 lalyt`a#dstuмygYDg5gYh5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jzh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH stն||qaT|G $If^gd`a $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykd$$Ifl0  t0'84 lalyt`a¶жѶҶԶնֶػɛػػylh`O;O'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jRh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jfh5 OJQJU^JmH sH ?NLG>2 $$Ifa$gd`a $Ifgd`agd5 kd$$Iflr '7&8 t0'4 lalyt`a?NOP^_`;w`wI-jzh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH 'h/h5 5CJOJQJ^JmH sH NOadʷ˷|||pp|| $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`aʷ˷̷ͷ۷ܷݷVWXfghlĹ~rhQr>r3h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH ˷̷޷S9000 $Ifgd`akd$$IflTֈL| '7k008 t0'4 lalyt`aSVWilSJJJ $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a̸͸θѸҸ۸ۦt_tJt?h5 6OJQJ^J)jeh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jyh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  "#$&򾱭}udPdPd;)h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 h5 5CJOJQJ^Jh5 56OJQJ^J#jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH "#$)kdQ$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a$9MZQQQ $Ifgd`aykdj$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`agd5 ^gd5 9:HIJLMN\]^`absκpYH;h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-j%h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH Mbstu$kdy$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`astuvўt]L?h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH u&' $$Ifa$gd`a $Ifgd`a'()789=»ĻŻƻػٻڻìӠvà_NAh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j+h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^J'(:=9000 $Ifgd`akd$$IflֈL| '7k008 t0'4 lalyt`aƻ׻ػ $Ifgd`a $$Ifa$gd`aػٻM9000 $Ifgd`akdq$$Ifl\ֈL| '7k008 t0'4 lalyt`aMPQR`abcuvwȵȫԛԛțrdOr@rdh5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH MPQcfvSJJ? <$Ifgd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a¼üļʼۼܼݼ߼8:ػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j{h5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH vʼۼܼ $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`aܼݼ9:LC>-Y$If^Y`gd`agd5 ^gd5 kdg$$IflrL '7k`8 t0'4 lalyt`a:BķmaN7a-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j;h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH  yppppp $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a  +,-1wxij~g[H1-j4h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH .1w9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a¾þľȾ,-.012@𨛎lYB-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH -jAh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH w $Ifgd`a $$Ifa$gd`ažȾ9000 $Ifgd`akd$$IflPֈL| '7k008 t0'4 lalyt`a1FWX $Ifgd`a $$Ifa$gd`a@ABDEFXY[ij{iaP;&)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH XY90++gd5 ^gd5 kd$$IflFֈL| '7k008 t0'4 lalyt`ah____ $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`aҾq嘈Z嘈C-j`h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH 'h/h5 CJH*OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^J_VVVVJJV $$Ifa$gd`a $Ifgd`akdq$$Ifl\L 7k` t0'84 lalyt`a#$%*69:;Iĺs`sU>s`s-jh5 CJOJQJU^JmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j)h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH &kd$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a&'*7kd$$IflTrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a69:L7kd $$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`aIJKQ$%345789GHIKȵȫȫԛԛȵԛmԛԛVԛ-jh5 CJOJQJU^JmH sH -jkh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j9h5 CJOJQJU^JmH sH LMQ7kd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a$Jkd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a$8M^_ $Ifgd`a $$Ifa$gd`aKLM^_`aopqrv1456DEFGKĺs`sIs`s-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH _`rs& $Ifgd`akdI$$Ifl֞L| '774008 t0'4 lalyt`asv145GH7kd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`aHK7kd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`aĸĦt_tJt?h5 6OJQJ^J)jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH  $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a <$Ifgd`aknʽ|tcT@0h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J!h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 h5 5CJOJQJ^Jh5 56OJQJ^Jh5 OJQJ^JmH sH #jh5 OJQJU^JmH sH )jvh5 OJQJU^JmH sH lmnLC>>-Y$If^Y`gd`agd5 ^gd5 kd$$IflrL '7k`8 t0'4 lalyt`a yppp $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a $$Ifa$gd`a "#$23ȵԥȵȄ|gZKԥ4-jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH h5 OJQJ^J-j9h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH  _VVVJ $$Ifa$gd`a $Ifgd`akd6$$Ifl\L 7k` t0 4 lalyt`a"_ZI= $$Ifa$gd`aY$If^Y`gd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`a"#5|i] $$Ifa$gd`aX<$If^X`gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a345=+ιߜߔrcS<ιS-j h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH h5 CJH*OJQJ^Jh5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH rm\P $$Ifa$gd`aY$If^Y`gd`agd5 kd$$Ifl(FL ` t0     4 lalyt`a2GXY|i]]|| $$Ifa$gd`a<$If^`gd`a $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a+,-/123ABCEFGXYZ\ijĐreUB0"h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j9 h5 CJOJQJU^JmH sH YZLC>+Y<$If^Y`gd`agd5 ^gd5 kd% $$IflrL| '008 t0'4 lalyt`a 123ABCFGU˷rdOr@rdh5 6OJQJ^JmH sH )jo h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^J-j h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH h5 mH sH  "2nyppeUHp $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykd> $$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aUVWZ[ijkmno}~!ػɛػػylh`O:)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j[h5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j h5 OJQJU^JmH sH "?:)$If^`gd`agd5 kdG$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a!"123ABCGvwκt]L5-jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH "12DGvyppppp $Ifgd`aykd`$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a  !"45ŵ~kaJ-j%h5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH  9000 $Ifgd`akd}$$IflֈL| '7k008 t0'4 lalyt`a "%5SJJ? <$Ifgd`a $Ifgd`akd"$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a56DEFIJXYZ]^lmnpqrߦߑqdWSh5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH 5q $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a?LC>-$If^`gd`agd5 ^gd5 kds$$IflrL '7k`8 t0'4 lalyt`a>?NOP^_`d{gW@g4h5 CJOJQJ^J-jGh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH  ?NOadyppppp $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a dɲɡ~m`SCh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j3h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH y9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`ay|}~ȵȫԛԛțrdOr@rdh5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jQh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH y|}SJJ? <$Ifgd`a $Ifgd`akdN$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a dfػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j)h5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j=h5 OJQJU^JmH sH  $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a efLC>-$If^`gd`agd5 ^gd5 kd$$IflrL '7k`8 t0'4 lalyt`afo;<JKLNķueNuue7ue-j"h5 CJOJQJU^JmH sH -j"h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH yppp $Ifgd`aykd $$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a;Qfw_VVVVJJV $$Ifa$gd`a $Ifgd`akds!$$Ifl\L 7k` t0'84 lalyt`aNPQR`abdefxyzξξ|ξeξNξξ-j%h5 CJOJQJU^JmH sH -jG%h5 CJOJQJU^JmH sH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jp#h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH wxykd#$$Ifl֞L| '774008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a $Ifgd`a)ijvԍcYčYBčc-j*h5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH -j'h5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j&h5 CJOJQJU^JmH sH & $Ifgd`akd&$$IflR֞L| '774008 t0'4 lalyt`a7kdH($$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a)=Jkdo)$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a)*89:<=>LMNPQRdeftuvw{۸ۡېvlU۸Bl$h/h5 CJOJQJ^JmH sH -j'-h5 CJOJQJU^JmH sH h5 OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jz+h5 CJOJQJU^JmH sH h5 CJOJQJ^J-j+h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH =Rcd $Ifgd`a $$Ifa$gd`adewx& $Ifgd`akd+$$Ifl֞L| '774008 t0'4 lalyt`ax{017kd-$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a-./04nqrs ./015ilmn|}~𹦹𹦹n𹦹W𹦹-jc3h5 CJOJQJU^JmH sH -j1h5 CJOJQJU^JmH sH -jE0h5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j.h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH "14nqr7kd,/$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a127kd0$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a25ilm7kdJ2$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a7kd3$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a)*+9:;>?MNORSabceһүҝzkVkAk)jT6h5 OJQJU^JmH sH )j5h5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jh5h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^J-j4h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^J*f~ $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a <$Ifgd`aefguvwx~KL[ԿԲ|tcN9)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j6h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^JLLC>-$If^`gd`agd5 ^gd5 kd@7$$IflrL '7k`8 t0'4 lalyt`aL[\nqyppppp $Ifgd`aykdY8$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a [\]klmͶݪ͓ͪ|k^QAh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j9h5 CJOJQJU^JmH sH -j9h5 CJOJQJU^JmH sH h5 CJOJQJ^J-j9h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Ji9000 $Ifgd`akdh:$$IflֈL| '7k008 t0'4 lalyt`ailmn|}~ȵȫԛԛțrdOr@rdh5 6OJQJ^JmH sH )j=h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -j=h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j;h5 CJOJQJU^JmH sH ilmSJJ? <$Ifgd`a $Ifgd`akd <$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`aTVػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j>h5 OJQJU^JmH sH h5 6OJQJ^J)jr>h5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j=h5 OJQJU^JmH sH  $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`aUVWLC>-$If^`gd`agd5 ^gd5 kd^?$$IflrL '7k`8 t0'4 lalyt`aVWfghvwxy"#%&')*9:;IκvaQD<κh5 mH sH h5 CJH*OJQJ^Jh5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J-jNAh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH Wfgy#&yp]<$If^`gd`a $Ifgd`aykdw@$$Ifl0L L` t0 4 lalyt`a $$Ifa$gd`a&'()*9rmmdX $$Ifa$gd`a $Ifgd`agd5 kdA$$IflFL ` t0     4 lalyt`a9:L|qe $$Ifa$gd`a <$Ifgd`a $Ifgd`aykdB$$Ifl0L L` t0 4 lalyt`aIJKLUȷȅ}y}h[J:h5 CJOJQJ^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH h5 h5 mH sH h5 CJH*OJQJ^Jh5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jCh5 CJOJQJU^JmH sH rmmbV $$Ifa$gd`a <$Ifgd`agd5 kdC$$IflFL ` t0     4 lalyt`a=Ufg||qaT|G $If^gd`a $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykdD$$Ifl0  t0'84 lalyt`a$%&)*89:<ĸsdOd:d)jFh5 OJQJU^JmH sH )jFh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jFh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jEh5 CJOJQJU^JmH sH <=>LMNOUfghiprԿԲu^I:h5 5CJOJQJ\^J)h5 5CJOJQJ^JmH nH sH tH ,h5 5CJOJQJ\^JmH nH sH tH $h5 5CJOJQJ\^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jpGh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^JghiLG6* $$Ifa$gd`a$If^`gd`agd5 kdG$$Iflr '7&8 t0'4 lalyt`a %;Pab|||pp|| $$Ifa$gd`a $Ifgd`aykdH$$Ifl0L L` t0'84 lalyt`a%&4568:;<JKLNOPabcdrۡېyh[N>h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jJh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j0Jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jIh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH bcux9000 $Ifgd`akdK$$IflֈL| '7k008 t0'4 lalyt`arstԸԸԸyԸh[N>Ըh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j7Mh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jLh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jKLh5 CJOJQJU^JmH sH  $Ifgd`a $$Ifa$gd`a9000 $Ifgd`akdM$$Ifl\ֈL| '7k008 t0'4 lalyt`aȵȪԚȵyԚbȵyԚKԚȵ-j9Sh5 CJOJQJU^JmH sH -jQh5 CJOJQJU^JmH sH h5 OJQJ^J-jGPh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jNh5 CJOJQJU^JmH sH SJJJ $Ifgd`akdDO$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`a_VVVJ $$Ifa$gd`a $Ifgd`akdP$$Ifl\L 7k` t0'84 lalyt`a_VVI= $$Ifa$gd`a L$If]Lgd`a $Ifgd`akd6R$$Ifl\L 7k` t0'84 lalyt`aŮŜyjUj@j)jVh5 OJQJU^JmH sH )jUh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )j(Uh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jTh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^J_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akdS$$Ifl\L 7k` t0'84 lalyt`a/013ԿԲ|tcN9)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jVh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^J/01)kdW$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a1_sZQQQ $Ifgd`aykdX$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`agd5 ^gd5 _`noprstͶݪ̀ͪiXK>h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jYh5 CJOJQJU^JmH sH -jJYh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jXh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Js$kd(Z$$IflֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a#$234689:HIJƵzơcR١;-jT]h5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j\h5 CJOJQJU^JmH sH -jv\h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h/h5 OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 6OJQJ^Jh5 CJOJQJ^JnH tH Jkde[$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a#9N_` $$Ifa$gd`a $Ifgd`aJLMN_`abpqrŵ}qZIq!h5 CJH*OJQJ^JmH sH -j_h5 CJOJQJU^JmH sH h5 CJOJQJ^J-j_h5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ\^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH `ast& $Ifgd`akd]$$Ifl֞L| '774002 t0'4 lalyt`atw $$Ifa$gd`a $Ifgd`aij~g[H[~5%h5 CJH*OJQJ^JaJmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jah5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j_h5 CJOJQJU^JmH sH & $Ifgd`akdq`$$Ifl֞L| '774002 t0'4 lalyt`a7.^gd5 kdb$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a56EFGUVW[{kT{H5{k$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jch5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH 6EFX[kykd7c$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`agd5 ĸġĐvf[DԸ-jufh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jdh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jhdh5 CJOJQJU^JmH sH 9000 $Ifgd`akdFe$$IflֈL| '7k008 t0'4 lalyt`a589:HIJNóózócó-jjh5 CJOJQJU^JmH sH -jYih5 CJOJQJU^JmH sH h5 OJQJ\^J-jgh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH 58SJJJ $Ifgd`akdf$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a89KN_VVVJ $$Ifa$gd`a $Ifgd`akdVh$$IflT\L 7k` t0'84 lalyt`a_VVVJ $$Ifa$gd`a $Ifgd`akdi$$Ifl\L 7k` t0'84 lalyt`a TW_VVVJ $$Ifa$gd`a $Ifgd`akdHk$$Ifl\L 7k` t0'84 lalyt`a TWXYghij|}~ĸăĸqcNq?qch5 6OJQJ^JmH sH )j:nh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jmh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jKlh5 CJOJQJU^JmH sH WXjm}_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akdl$$Ifl\L 7k` t0'84 lalyt`a?BػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)joh5 OJQJU^JmH sH h5 6OJQJ^J)j&oh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jnh5 OJQJU^JmH sH )kdp$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a@BZQQQ $Ifgd`aykd+q$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`agd5 ^gd5 BK ķmaN7a-j\rh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jqh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH  !#$%6789GHIijxyz|}~ij~g[D[-jth5 CJOJQJU^JmH sH h5 CJOJQJ^J-jith5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jrh5 CJOJQJU^JmH sH %678$kd:s$$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a8JMi} $$Ifa$gd`a $Ifgd`a #$%3459ijwkXkM6k-jWxh5 CJOJQJU^JmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jvh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jGuh5 CJOJQJU^JmH sH  9000 $Ifgd`akdu$$IflFֈL| '7k008 t0'4 lalyt`a #$69SJJJ $Ifgd`akdTw$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`a9+,-.1óóózócóQ#jh5 OJQJU^JmH sH -j|h5 CJOJQJU^JmH sH h5 6OJQJ^J-jI{h5 CJOJQJU^JmH sH -jyh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH _VVVJ $$Ifa$gd`a $Ifgd`akdx$$Ifl\L 7k` t0'84 lalyt`a.1_VVVJ $$Ifa$gd`a $Ifgd`akdFz$$Ifl\L 7k` t0'84 lalyt`a_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd{$$Ifl\L 7k` t0'84 lalyt`a ,-./5FGHJ˼˼˼reXTA%h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j~h5 OJQJU^JmH sH h5 6OJQJ^J)j$~h5 OJQJU^JmH sH )j}h5 OJQJU^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j8}h5 OJQJU^JmH sH h5 OJQJ^JmH sH 5FGH)kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`aJ )*+/OP^{kT{H5{k$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH H ,/OcZQQQ $Ifgd`aykd)$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`agd5 ^gd5 ^_`bcdrstvwxĸġĐvf[DԸ-jgh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jZh5 CJOJQJU^JmH sH cx$kd8$$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a $$Ifa$gd`a $Ifgd`aɲɦɏ~qdTIh5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jEh5 CJOJQJU^JmH sH h5 CJOJQJ^J-j݃h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH C9000 $Ifgd`akd$$IflRֈL| '7k008 t0'4 lalyt`aCDRSTVWXfghjkl}~ȵԥԥԥwԥfYL<h5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jRh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH CWl}~ $Ifgd`a $$Ifa$gd`a~9000 $Ifgd`akd0$$IflFֈL| '7k008 t0'4 lalyt`a~  й୚y୚bЭK-jʌh5 CJOJQJU^JmH sH -jQh5 CJOJQJU^JmH sH -j؉h5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j_h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^J SJJJ $Ifgd`akdՈ$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a_VVVJ $$Ifa$gd`a $Ifgd`akdN$$Ifl\L 7k` t0'84 lalyt`a-i_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akdNj$$Ifl\L 7k` t0'84 lalyt`a,-.<=>ABPQRUVdefhijxyz{۽vaVA)jh5 OJQJU^JmH sH h5 6OJQJ^J)j,h5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )j@h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH i)kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a{1@ABPQRSefIJtdMtdA1h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jސh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 h5 5CJOJQJ^Jh5 56OJQJ^J1@ASVf`WW $Ifgd`aykd1$$Ifl0  t0'84 lalyt`a $$Ifa$gd`a <$Ifgd`agd5 ^gd5 fguvwz{ߦߑqdWSKh5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j@h5 OJQJU^JmH sH )jʑh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jTh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH f $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a+LG6* $$Ifa$gd`aY$If^Y`gd`agd5 kd,$$Iflr '7&8 t0'4 lalyt`a+,-;<=destuwxyķmaJa3-jޕh5 CJOJQJU^JmH sH -jvh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH +,>Adx|||pp|| $$Ifa$gd`a $Ifgd`aykdE$$Ifl0L L` t0'84 lalyt`a&'(*+,:ʽ~r_Hr-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH 9000 $Ifgd`akdT$$Ifl|ֈL| '7k008 t0'4 lalyt`a+@QR $Ifgd`a $$Ifa$gd`a:;<>?@RSTbcdhijwkXAk-jnh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jah5 CJOJQJU^JmH sH RSeh9000 $Ifgd`akdט$$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`aPSTUXijwkXkNkXkh5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j{h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j֚h5 CJOJQJU^JmH sH P9000 $Ifgd`akdL$$IflFֈL| '7k008 t0'4 lalyt`aPSTUXSJJJ $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`ax{_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`ax{|}ȵȫԛԛțrdOr@rdh5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jph5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH {|_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akdm$$Ifl\L 7k` t0'84 lalyt`a ceػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jHh5 OJQJU^JmH sH h5 6OJQJ^J)jҡh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j\h5 OJQJU^JmH sH )kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`ade#bykdף$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`agd5 ^gd5 en ķmaN7a-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH  #$%&456:ij~g[H1-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jph5 CJOJQJU^JmH sH #$%7:0kd$$IflqֈL| '7k008 t0'4 lalyt`a $Ifgd`aMPQR`𨛎lYNh5 OJQJ\^J$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH  $Ifgd`a $$Ifa$gd`aM9000 $Ifgd`akdi$$IflFֈL| '7k008 t0'4 lalyt`aMPQcfSJJJ $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`a`abf PQ`aȵȫ~mXC6'h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH  Q`_VQH< $$Ifa$gd`a $Ifgd`agd5 ^gd5 kdy$$Ifl\L 7k` t0'84 lalyt`a`abe|||p $$Ifa$gd`a $Ifgd`aykd|$$Ifl0L L` t0'84 lalyt`aaeRSabcefguvwyz{ϻừ}fUHh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j&h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH -jHh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^JRf{_VVVVJJV $$Ifa$gd`a $Ifgd`akd7$$Ifl\L 7k` t0'84 lalyt`a{=@ABPQRVóÐ}póYÐ}O<%h5 CJH*OJQJ^JaJmH sH h5 OJQJ^J-j~h5 CJOJQJU^JmH sH h5 6OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jkd$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a=@AS7kdW$$IflTrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`aSV^`JA<gd5 ^gd5 kd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a]`i9:H{kT{H5{k$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH `9Mbsth_____ $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`a HIJLMN\]^`abstuvĸġĐvf[DԸ-j5h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j(h5 CJOJQJU^JmH sH tu%9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a%()*89:>uxyzóózóhZEh)jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 OJQJ\^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH %();>uxSJJJ $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`axy_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a`лЦІylhUC"h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j{h5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )kdg$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`aabcd`WW $Ifgd`aykd$$Ifl0  t0'84 lalyt`a $$Ifa$gd`a <$Ifgd`agd5 ^gd5 `dɵr`R=`.`h5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j-h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH h5 mH sH /012;˼˼zmiaP;)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH /0 $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a012LG6* $$Ifa$gd`aY$If^Y`gd`agd5 kd{$$Iflr '7&8 t0'4 lalyt`a κpYH;h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j-h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jOh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH  |||pp|| $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a !}~ўtcL;!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jHh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH  !}9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a} $Ifgd`a $$Ifa$gd`a23ABCEFGUVWYʶpYB-j%h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jUh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J29000 $Ifgd`akd&$$IflFֈL| '7k008 t0'4 lalyt`a2F[lm $Ifgd`a $$Ifa$gd`aYZ[lmno}~Ĺ~r_Hr-j@h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH mn9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a  $Ifgd`a $$Ifa$gd`a    ./04lopqij~g[H[>h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jMh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH 14l9000 $Ifgd`akd$$IfltֈL| '7k008 t0'4 lalyt`alopSJJJ $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`aĸăĸybĸPBh5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 OJQJ^J-j?h5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH _VVVJ $$Ifa$gd`a $Ifgd`akd<$$Ifl\L 7k` t0'84 lalyt`a _VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a   "3457ػػɆػqػdWS@%h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )j.h5 OJQJU^JmH sH  "345)kd$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a7-./123i]J3]-jPh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH 52GXbykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`agd5 ^gd5 3ABCEFGXYZ[ijko𴧚h\I2-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j]h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH XYZlo0kd.$$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a |𨛎lYNh5 OJQJ\^J$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j;h5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH  $Ifgd`a $$Ifa$gd`a  |9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a|SJJJ $Ifgd`akdH$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`a;=>MNO]ȵȫ~i\M=h5 CJOJQJ^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jKh5 CJOJQJU^JmH sH <=>M_VQH< $$Ifa$gd`a $Ifgd`agd5 ^gd5 kd$$Ifl\L 7k` t0'84 lalyt`aMN`|i] $$Ifa$gd`a<$If^`gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a]^_`i-<=>LȷȅzraTC3h5 CJOJQJ^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH h5 mH sH h5 6OJQJ^Jh5 CJH*OJQJ^Jh5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH -<rmZN $$Ifa$gd`aY<$If^Y`gd`agd5 kd$$IflFL ` t0     4 lalyt`a<=ORb||qaT|G $If^gd`a $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykd$$Ifl0  t0'84 lalyt`aLMNOabcqrsvwĸsdOd:d)j h5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )j!h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH  GHIԿԲs^OC6h5 CJH*OJQJ^Jh5 CJOJQJ^Jh5 5CJOJQJ\^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^J LG>2 $$Ifa$gd`a $Ifgd`agd5 kd$$Iflr '7&8 t0'4 lalyt`aGH|||p $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`aHI[\_z_VVVVJJV $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`aIJXYZz{ۡ۸ۊyl_T=-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -jTh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH kd@$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a       l o p q         ' ( ) * 8 9 : ;     «ߘߍvߘlߍlUl-jmh5 CJOJQJU^JmH sH h5 OJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH -j"h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 6OJQJ\^Jh5 CJOJQJ^J'jh5 CJOJQJU^JmH sH      7kd $$IflTrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a   l o p  7kd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a       7kd'$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a  ' ( ) ; < ? } Jkd\$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a}       @7777 $Ifgd`akd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a                    ! / ĸăĸqcNq?qch5 6OJQJ^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j h5 CJOJQJU^JmH sH      @77 $Ifgd`akd$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a  H ` q r  $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a <$Ifgd`a/ 0 1 4 5 C D E G H I W X Y Z ` q r s u   ػɛػػylhUC;h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j h5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH r s   A LC>-$If^`gd`agd5 ^gd5 kd$$IflrL '7k`8 t0'4 lalyt`a  @ A P Q R ` a b           ķmaJa3-jh5 CJOJQJU^JmH sH -j?h5 CJOJQJU^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH A P Q c f      yppppp $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a             < = K L M O P Q _ ʽ~r_Hr-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jLh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH     < 9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a< P e v w  $Ifgd`a $$Ifa$gd`a_ ` a c d e w x y           ijwkXAk-j7h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j*h5 CJOJQJU^JmH sH w x    9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a &' $Ifgd`a $$Ifa$gd`a'()789:=ijwkXkT=k-jh5 CJOJQJU^JmH sH h5 $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jDh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH '(:=900% <$Ifgd`a $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`aSJJ? <$Ifgd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a)*+лެЗެЂެwbUHDwh5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jh5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )j%h5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^JmH sH )* $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a*+LC>-$If^`gd`agd5 ^gd5 kd$$IflrL '7k`8 t0'4 lalyt`a+-{gW@g4h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH  0DYjkyppppp $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a 01?@ACDESTUWXYjklm{ɲɦɏ~qdTIh5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-jGh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH kl~9000 $Ifgd`akd%$$IflFֈL| '7k008 t0'4 lalyt`a{|}ȵԥԥԥwԥfYLAԥh5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j2h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jTh5 CJOJQJU^JmH sH  $Ifgd`a $$Ifa$gd`al9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`alm{|}ȵԥԥԥwԥfYLAh5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -j?h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH l $Ifgd`a $$Ifa$gd`a90+gd5 ^gd5 kd$$IflFֈL| '7k008 t0'4 lalyt`a^_nop~{gW@g4gWh5 CJOJQJ^J-j h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH _noh_____ $Ifgd`aykdL $$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`a ĸġĐvf[DԸ-j h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j h5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j} h5 CJOJQJU^JmH sH 9000 $Ifgd`akd[ $$IflFֈL| '7k008 t0'4 lalyt`aFHQ|}ó~ldS>))h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ\^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH SJJJ $Ifgd`akd $$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`aGH}_VQH< $$Ifa$gd`a $Ifgd`agd5 ^gd5 kdk$$IflT\L 7k` t0'84 lalyt`a}-.<=>@BCDRİzcĊzLz;׊z!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH -j:h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH 'h/h5 CJH*OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^Jh5 5CJOJQJ^J|||p $$Ifa$gd`a $Ifgd`aykdn$$Ifl0L L` t0'84 lalyt`a-CXi_VVVVJJV $$Ifa$gd`a $Ifgd`akd)$$Ifl\L 7k` t0'84 lalyt`aRSTVWXjklz{|}ijwkXkAkX-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j&h5 CJOJQJU^JmH sH ijk}kd$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a}~7kds$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a-. $$Ifa$gd`a $Ifgd`a./0>?@DĸġĐvkTԸA$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jjh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH ./AD9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`aSJJJ $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`aй୚yЭgYDg)jwh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ\^J_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`aqлЦІylhUC"h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)jch5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )kdO$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`ars[jk}ZQQQ $Ifgd`aykdh$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`agd5 ^gd5 qs|Z[jklz{|ҽ}fZG}0}-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j#h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH 34Bξξ|laξJ7ξ$h/h5 CJOJQJ^JmH sH -j!h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH $kd $$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a3G\mn $$Ifa$gd`a $Ifgd`aBCDFGHVWXZ[\noqĸġĐvkXF>-!h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j"h5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j*"h5 CJOJQJU^JmH sH no90+gd5 ^gd5 kd#$$IflFֈL| '7k008 t0'4 lalyt`a*+:;<JKLghvwxz{|ȹ~r[rD-j%h5 CJOJQJU^JmH sH -jh%h5 CJOJQJU^JmH sH h5 CJOJQJ^J-j$h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH +:;MPg{h_____ $Ifgd`aykd7$$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`a Ĺ~r_Hr-j'h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-ju'h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH 9000 $Ifgd`akdF&$$IflFֈL| '7k008 t0'4 lalyt`a $Ifgd`a $$Ifa$gd`a)*+/twxzijwkXkM:%h5 CJH*OJQJ^JaJmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j)h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jS(h5 CJOJQJU^JmH sH ,/t9000 $Ifgd`akd($$IflFֈL| '7k008 t0'4 lalyt`atwx&SJE4$If^`gd`agd5 ^gd5 kd`*$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`az%&56:opqp^J:#-j/-h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH  &567:noyppp $Ifgd`aykdc+$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aop_VVVVJJV $$Ifa$gd`a $Ifgd`akd,$$Ifl\L 7k` t0'84 lalyt`aϸϧϐreZC-j/h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j.h5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j-h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH kd.$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a.?@ $$Ifa$gd`a $Ifgd`a()*,-.@ABPQRxyijĐreZCԧ-j2h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j0h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jZ0h5 CJOJQJU^JmH sH @AST& $Ifgd`akdF1$$IflF֞L| '774008 t0'4 lalyt`aTWx $$Ifa$gd`a $Ifgd`aijĐreZG5#h/h5 6OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jw3h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j3h5 CJOJQJU^JmH sH & $Ifgd`akd3$$IflF֞L| '774008 t0'4 lalyt`a9Jkd@5$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a9<=>LMNOS˴˨t˨iR˨-j}9h5 CJOJQJU^JmH sH h5 6OJQJ^J-j7h5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jQ6h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h/h5 OJQJ^JmH sH 9<=OPS@7777 $Ifgd`akd6$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a@7777 $Ifgd`akdd8$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`ad @7777 $Ifgd`akd9$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`ad g h i w x y z ~  !!!!!!!!!!!!!!!ĸăĸybĸyK-j?h5 CJOJQJU^JmH sH -j8>h5 CJOJQJU^JmH sH h5 OJQJ^J-j<h5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j ;h5 CJOJQJU^JmH sH d g h z { ~  @7777 $Ifgd`akd;$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a !!!!!!@777 $Ifgd`akd=$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a!!!!/"2"_VVVJ $$Ifa$gd`a $Ifgd`akd>$$Ifl\L 7k` t0'84 lalyt`a!!!/"2"3"4"B"C"D"E"W"X"Y"g"h"i"l"m"{"|"}""""Ʋ{fW{BW{)jBh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jAh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH -j*Ah5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 2"3"E"H"X""_VVK;$$If^a$gd`a <$Ifgd`a $Ifgd`akd'@$$Ifl\L 7k` t0'84 lalyt`a"""""""""""""""##(#ɾذذ}jXP?!h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jCh5 OJQJU^JmH sH h5 OJQJ^JmH sH h5 6OJQJ^Jh5 6OJQJ^JmH sH #jh5 OJQJU^JmH sH )jBh5 OJQJU^JmH sH """"")kdxC$$IflrL '7k`8 t0'4 lalyt`a $If^gd`a $Ifgd`a $If^gd`a"#########ZQ $Ifgd`aykdD$$Ifl0L L` t0 4 lalyt`a $$Ifa$gd`a$If^`gd`agd5 ^gd5 (##########j$m$n$o$}$~$$$$$ȹ~r_rT=r_r-jFh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jLEh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH ##j$m$n$$$$$JkdE$$Ifl\L 7k` t0 4 lalyt`a $$Ifa$gd`a $Ifgd`a$$$$$_ZI= $$Ifa$gd`a$If^`gd`agd5 kd;G$$Ifl\L 7k` t0 4 lalyt`a$$$$$$$$$$$%Z%[%^%_%`%a%p%q%̽veP=v2̽h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J-jIh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH h5 OJQJ^J$$$[%^%|k_ $$Ifa$gd`a$If^`gd`a $Ifgd`aykd>H$$Ifl0L L` t0 4 lalyt`a^%_%`%a%p%rm\P $$Ifa$gd`a$If^`gd`agd5 kdI$$IflFL ` t0     4 lalyt`ap%q%%%%&&&|i]]|| $$Ifa$gd`a<$If^`gd`a $Ifgd`aykdxJ$$Ifl0L L` t0'84 lalyt`aq%r%%%%%%%%%%%%%%%%&&&&븧kZC-j;Lh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jKh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 CJOJQJ^J-jOKh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH &&&&&&&v&z&&a'b'q'r'v'Ĺ{fQB6h5 CJOJQJ^Jh5 5CJOJQJ\^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH &&w&x&z&&&LC>>55 $Ifgd`agd5 ^gd5 kdL$$IflrL| '008 t0'4 lalyt`a&N'b'q'r's'v'''_ykdM$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`as$If^`sgd`av'''''''''((*(+(,(.(0(1(2(@(A(B(D(E(F(²²²s²\²K>h5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jtPh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jOh5 CJOJQJU^JmH sH -jOh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH '''''(1(F(W(_VVVVJJV $$Ifa$gd`a $Ifgd`akdN$$Ifl\L 7k` t0'84 lalyt`aW(X(Y(k(kdP$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`aF(X(Y(Z(h(i(j(o(((((((((((((((((((ìӠvà_NAh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j)Sh5 CJOJQJU^JmH sH -jRh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jKRh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jk(l(o(((((( $$Ifa$gd`a $Ifgd`a((((& $Ifgd`akdS$$IflF֞L| '774008 t0'4 lalyt`a((((=)>)L)M)N)P)R)S)T)b)c)d)f)g)h)z)ȵԥԥ}ԥfԥUH;h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jUh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jZUh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jTh5 CJOJQJU^JmH sH ((=)S)h)y)z) $$Ifa$gd`a $Ifgd`az){)|))& $Ifgd`akdFV$$IflF֞L| '774008 t0'4 lalyt`az){)|))*******s*t************ų䈟şq`؟I-jYh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j Yh5 CJOJQJU^JmH sH -jXh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH h5 6OJQJ^J)******s*JkdW$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`as***** $Ifgd`a $$Ifa$gd`a**********B+C+Q+R+S+U+V+W+e+f+g+i+j+k+}+ɵoXA-j/\h5 CJOJQJU^JmH sH -j[h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jQ[h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH ****& $Ifgd`akd Z$$IflF֞L| '774008 t0'4 lalyt`a**B+V+k+|+}+ $$Ifa$gd`a $Ifgd`a}+~+++& $Ifgd`akd\$$Iflc֞L| '774008 t0'4 lalyt`a}+~++++++++++++++++++++ , ,һ⯜҅үn]PCh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j^h5 CJOJQJU^JmH sH -jR^h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j]h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^J+++++, , $$Ifa$gd`a $Ifgd`a , ,f,&^gd5 kd0_$$IflF֞L| '774008 t0'4 lalyt`a , ,e,g,o,,,,,,j-k-y-{o\H8h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH  f,g,,,,,,h-i-cZZZ $Ifgd`aykdg`$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`aY$If^Y`gd`agd5 i-j-|-}------_VVVVJJV $$Ifa$gd`a $Ifgd`akd"a$$Ifl>\L 7k` t0'84 lalyt`ay-z-{--------------------ԸԸԸyԸh[NԸh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jch5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jbh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j3bh5 CJOJQJU^JmH sH ----kdc$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a----..!.".#.%.&.'.5.6.7.9.:.;.M.N.O.].ȵԥԥԥwԥfYLԥh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jeh5 CJOJQJU^JmH sH -j^eh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jdh5 CJOJQJU^JmH sH ---.&.;.L.M. $$Ifa$gd`a $Ifgd`aM.N.`.c.& $Ifgd`akd!h5 5CJOJQJ^JmHsH!h5 5CJOJQJ^JmH sH h5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)j oh5 OJQJU^JmH sH h5 6OJQJ^J)jnh5 OJQJU^JmH sH )j nh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH 00000161gd5 kdo$$Iflr '7&8 t0'4 lalyt`a $If^gd`a $Ifgd`a01111#1111111111111ȹtdMttd6td-jrh5 CJOJQJU^JmH sH -jgrh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH #h/h5 6OJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^Jh5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH 111 1#111yppp $Ifgd`aykdp$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a111111111_VVVVJJV $$Ifa$gd`a $Ifgd`akdVq$$Ifl\L 7k` t0'84 lalyt`a11111111111111112=2@2A2B2P2ξξ|qξZG:ξh5 6OJQJ\^J$h/h5 CJOJQJ^JmH sH -j*uh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jSsh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH 1112kds$$IflF֞L| '774008 t0'4 lalyt`a $Ifgd`a222=2@2A2S27kdu$$IflTrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`aP2Q2R222222222222222222222ȽԭԭԭnԭWԭF!h5 CJH*OJQJ^JmH sH -j4yh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jxh5 CJOJQJU^JmH sH -jHxh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 6OJQJ^Jh5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jvh5 CJOJQJU^JmH sH S2T2W222227kd!w$$IflrL 774` t0'84 lalyt`a $$Ifa$gd`a $Ifgd`a2222222 $$Ifa$gd`a $Ifgd`a2222222223Y3\3]3_3333ǷǷvcQI8!h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jzh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J2223Y39000 $Ifgd`akdy$$IflFֈL| '7k008 t0'4 lalyt`aY3\3]333<4SJE4Y$If^Y`gd`agd5 ^gd5 kdA{$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a3;4<4K4L4M4[4\4]4444444444444ȹ~r[rD-j}h5 CJOJQJU^JmH sH -ju}h5 CJOJQJU^JmH sH h5 CJOJQJ^J-j|h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH <4K4L4^4a444444yppppp $Ifgd`aykdD|$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a 444444444447585F5G5H5J5K5L5Z5Ĺ~r_Hr-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH 4444759000 $Ifgd`akdS~$$IflFֈL| '7k008 t0'4 lalyt`a75K5`5q5r5 $Ifgd`a $$Ifa$gd`aZ5[5\5^5_5`5r5s5t5555556666666ijwkXkM6k-jph5 CJOJQJU^JmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j`h5 CJOJQJU^JmH sH r5s55559000 $Ifgd`akdր$$IflFֈL| '7k008 t0'4 lalyt`a5666666SJJJ $Ifgd`akdm$$IflT\L 7k` t0'84 lalyt`a $$Ifa$gd`a666666666666666667_7`7n7o7p7r7s7t77777óóóónóóWó-j@h5 CJOJQJU^JmH sH -j؆h5 CJOJQJU^JmH sH -jbh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^J$h/h5 CJOJQJ^JmH sH 666666_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a6667_7s7777_VVVJJVV $$Ifa$gd`a $Ifgd`akd_$$Ifl\L 7k` t0'84 lalyt`a777777777777777777Ĺ~r`R=`.h5 6OJQJ^JmH sH )jMh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH h5 CJOJQJ^J-j׈h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH 77777900% <$Ifgd`a $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a7777777777777 8 8 888%8&8'8)88ߦ߆ylhUC"h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j9h5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jÉh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH 778%8&8 $If^gd`a $Ifgd`a $If^gd`a$$If^a$gd`a&8'8888LC>-Y$If^Y`gd`agd5 ^gd5 kd%$$IflrL '7k`8 t0'4 lalyt`a8888888 9999>9?9M9N9O9Q9R9S9a9Ŷ{o\Eo-joh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH 88899>9R9g9x9y9yppppp $Ifgd`aykd>$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a a9b9c9e9f9g9x9y9z9{9999999999ij~g[H1-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j|h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j׍h5 CJOJQJU^JmH sH y9z99999000 $Ifgd`akdM$$IflFֈL| '7k008 t0'4 lalyt`a9999999999::: :!:":&:z:{::::::::𨛎lYB-jgh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jZh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH 999:: $Ifgd`a $$Ifa$gd`a::#:&:z:9000 $Ifgd`akdА$$IflFֈL| '7k008 t0'4 lalyt`az::::: $Ifgd`a $$Ifa$gd`a:::::::::;;;;;;;;ij{iaPA*-j/h5 CJOJQJU^JmH sH h5 5CJOJQJ\^J!h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 6OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jϒh5 CJOJQJU^JmH sH ::;;;90++gd5 ^gd5 kdE$$IflFֈL| '7k008 t0'4 lalyt`a;;;;;;6<9<h___ $Ifgd`aykdt$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`a;;;6<9<:<;<I<J<K<O<<<<<<<<<<=?=@=A=O=P=Q=U====뱚ߐynW-jh5 CJOJQJU^JmH sH h5 OJQJ\^J-j!h5 CJOJQJU^JmH sH h5 OJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH 9<:<L<O<<<_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a<<<<<=?=_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a?=@=R=U====>>_VVVJJVV $$Ifa$gd`a $Ifgd`akd$$IflT\L 7k` t0'84 lalyt`a=============>> >c>e>ijĐre[H6.h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jxh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH >>d>e>90+gd5 ^gd5 kd$$IflFֈL| '7k008 t0'4 lalyt`ae>m>>>? ????(?)?*?.?h?k?l?m?٭}mV}J7J,}h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jʜh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH ,h5 5CJH*OJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH e> ???+?.?h?k?h___ $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`ak?l?~????_VVVJ $$Ifa$gd`a $Ifgd`akd@$$Ifl\L 7k` t0'84 lalyt`am?{?|?}??????$$$$$$$$$$$$$$$$$$ŹŚŹl[D-jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j$h5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH Uh5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jCh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH ??$$$$$$$_VVVJJVV $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a FORMCHECKBOX c)Inclusion of an updated/amended Vaccine Antigen Master File, when changes do not affect the properties of the finished product FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. B.V.b.1 Update of the quality dossier following a Commission Decision following the procedure of Articles 30 or 31 of Directive 2001/83/EC or Articles 34 or 35 of Directive 2001/82/EC (referral procedure)Procedure type FORMCHECKBOX a)The change implements the outcome of the referral* FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The harmonisation of the quality dossier was not part of the referral and the update is intended to harmonise itII9 If one of the conditions is not met and the change is not specifically listed as Type II. B.V.c.1 Update of the quality dossier, to implement changes, requested by the EMEA/National Competent Authority, following assessment of a change management protocol.Procedure type FORMCHECKBOX a)The implementation of the change requires no further supportive data  FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The implementation of the change requires further supportive data IB FORMCHECKBOX c)Implementation of a change for a biological/immunological medicinal productIB9 If one of the conditions is not met and the change is not specifically listed as Type II. C.I Changes (Safety/Efficacy) to Human and Veterinary Medicinal ProductsProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  C.I.1 Change in the Summary of Product Characteristics, Labelling or Package Leaflet following a procedure in accordance with Articles 30 or 31 of Directive 2001/83/EC or Articles 34 or 35 of Directive 2001/82/EC (referral procedure)Procedure type FORMCHECKBOX a)The medicinal product is covered by the defined scope of the referral* FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The medicinal product is not covered by the defined scope of the referral but the change implements the outcome of the referral and no new additional data are submitted by the MAHIB FORMCHECKBOX c)The medicinal product is not covered by the defined scope of the referral but the change implements the outcome of the referral with new additional data submitted by the MAHII9 If one of the conditions is not met and the change is not specifically listed as Type II. C.I.2 Change in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference productProcedure type FORMCHECKBOX a)Implementation of change(s) for which no new additional data are submitted by the MAHIB FORMCHECKBOX b) Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH (e.g. comparability)II C.I.3 Implementation of change(s) requested by the EMEA/ National Competent Authority following the assessment of an Urgent Safety Restriction, class labelling, a Periodic Safety Update report, Risk Management Plan, Follow Up Measure/Specific Obligation, data submitted under Article 45/46 of Regulation (EC) No 1901/2006, or amendments to reflect a competent authority Core SPCProcedure type FORMCHECKBOX a)Implementation of agreed wording change(s) for which no new additional data are submitted by the MAHIB FORMCHECKBOX b)Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAHII Procedure type FORMCHECKBOX C.I.4 Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance dataII C.I.5 Change in the legal status of a medicinal product for centrally authorised productsProcedure type FORMCHECKBOX a)For generic/hybrid/biosimilar medicinal products following an approved legal status change of the reference medicinal productIB FORMCHECKBOX b)All other legal status changesII C.I.6 Change(s) to therapeutic indication(s)Procedure type FORMCHECKBOX a)Addition of a new therapeutic indication or modification of an approved oneII FORMCHECKBOX b)Deletion of a therapeutic indicationIB C.I.7 Deletion of:Procedure type FORMCHECKBOX a)a pharmaceutical formIB FORMCHECKBOX b)a strengthIB C.I.8 Introduction of a new Pharmacovigilance systemProcedure type FORMCHECKBOX a)which has not been assessed by the relevant national competent authority/EMEA for another product of the same MAHII FORMCHECKBOX b)which has been assessed by the relevant national competent authority/EMEA for another product of the same MAH*IB C.I.9 Changes to an existing pharmacovigilance system as described in the DDPS.Procedure type FORMCHECKBOX a)Change in the QPPV FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)Change in the contact details of the QPPV FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX c)Change of the back-up procedure of the QPPV FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX d)Change in the safety database (e.g. Introduction of a new safety database including transfer of safety data collection and/or analysis and reporting to the new system) FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX e)Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DDPS, in particular where the electronic reporting of ICSRs, the main databases, signal detection, or the compilation of PSURs is subcontracted. FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX f)Deletion of topics covered by written procedure(s) describing pharmacovigilance activities FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX g)Change of the site undertaking pharmacovigilance activities FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX h)Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system (e.g. change of the major storage/archiving location, administrative changes, update of acronyms, naming changes of functions/procedures). FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX i)Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH. FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. C.II Changes to Veterinary medicinal productsProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  Procedure type FORMCHECKBOX C.II.1 Variations concerning a change to or addition of a non-food producing target species.II C.II.2 Deletion of a food producing or non-food producing target species.Procedure type FORMCHECKBOX a)Deletion as a result of a safety issueII  FORMCHECKBOX b)Deletion not resulting from a safety issueIB  Procedure type FORMCHECKBOX C.II.3 Changes to the withdrawal period for a veterinary medicinal productII Procedure type FORMCHECKBOX C.II.4 Variations concerning the replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue.II Procedure type FORMCHECKBOX C.II.5 Variations concerning the replacement of a strain for a veterinary vaccine against equine influenzaII Procedure type FORMCHECKBOX C.II.6 Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics.IB D Changes to PMF/VAMFProcedure type FORMCHECKBOX z)Other variation FORMCHECKBOX IA  FORMCHECKBOX IB  FORMCHECKBOX II FORMCHECKBOX  Art 5 Implement. Date:  Procedure type FORMCHECKBOX D.1 Change in the name and/or address of the VAMF certificate holder FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.2 Change in the name and/or address of the PMF certificate holder FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.3 Change or transfer of the current PMF certificate holder to a new PMF certificate holder -i.e. different legal entity- FORMCHECKBOX IAIN FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.4 Change in the name and/or address of a blood establishment including blood/plasma collection centres FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.5 Replacement or addition of a blood/plasma collection centre within a blood establishment already included in the PMFIB Procedure type FORMCHECKBOX D.6 Deletion or change of status (operational/non-operational) of establishment(s)/centre(s) used for blood/plasma collection or in the testing of donations and plasma pools FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.7 Addition of a new blood establishment for the collection of blood/plasma not included in the PMFII Procedure type FORMCHECKBOX D.8 Replacement or addition of a blood centre for testing of donations and/or plasma pools within an establishment already included in the PMFIB Procedure type FORMCHECKBOX D.9 Addition of a new blood establishment for testing of donations and/or plasma pool not included in the PMFII Procedure type FORMCHECKBOX D.10 Replacement or addition of a new blood establishment or centre(s) in which storage of plasma is carried outIB Procedure type FORMCHECKBOX D.11 Deletion of a blood establishment or centre(s) in which storage of plasma is carried out FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.12 Replacement or addition of an organisation involved in the transport of plasma.IB Procedure type FORMCHECKBOX D.13 Deletion of an organisation involved in the transport of plasma FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.14 Addition of a CE-marked test kit to test individual donations as a new test kit or as a replacement of an existing test kit FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. D.15 Addition of a non-CE marked test kit to test individual donations as a new test kit or as a replacement of an existing test kitProcedure type FORMCHECKBOX a)The new test kit has not previously been approved in the PMF for any blood centre for testing of donationsII FORMCHECKBOX b)The new test kit has been approved in the PMF for other blood centre(s) for testing of donations FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.16 Change of kit/method used to test pools (antibody or antigen or NAT test).II Procedure type FORMCHECKBOX D.17 Introduction or extension of inventory hold procedure. FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.18 Removal of inventory hold period or reduction in its length.IB D.19 Replacement or addition of blood containers (e.g. bags, bottles)Procedure type FORMCHECKBOX a)The new blood containers are CE-marked FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)The new blood containers are not CE-markedII9 If one of the conditions is not met and the change is not specifically listed as Type II. D.20 Change in storage / transportProcedure type FORMCHECKBOX a)storage and/or transport conditions FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date:  FORMCHECKBOX b)maximum storage time for the plasma FORMCHECKBOX IA FORMCHECKBOX IB9Implement. Date: 9 If one of the conditions is not met and the change is not specifically listed as Type II. Procedure type FORMCHECKBOX D.21 Introduction of test for viral markers when this introduction will have significant impact on the viral risk assessment.II Procedure type FORMCHECKBOX D.22 Change in the plasma pool preparation (e.g. manufacturing method, pool size, storage of plasma pool samples)IB Procedure type FORMCHECKBOX D.23 Change in the steps that would be taken if it is found retrospectively that donation(s) should have been excluded from processing (look-back procedure).II     PAGE   PAGE 1/  NUMPAGES 33 Obr. 244-02 $$$$$$,%.%6%%% & & &&ɶvaR>.h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ\^Jh5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH $$-%.%90+gd5 ^gd5 kd$$IflFֈL| '7k008 t0'4 lalyt`a.%% & && &S&i&~&&&h_____ $Ifgd`aykd1$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a$If^`gd`a &&& &S&T&b&c&d&f&h&i&j&x&y&z&|&}&~&&ȵԥԥ}ԥfԥUH;h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jأh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jbh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH &&&&&&&&''''v'x''(ўn\TC.)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j}h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH &&&&'9000 $Ifgd`akdN$$IflFֈL| '7k008 t0'4 lalyt`a'''w'x'(SJE4$If^`gd`agd5 ^gd5 kd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a((.(/(0(>(?(@(D(((((((((((((κt]L5-jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j'h5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH (.(/(A(D((((((yppppp $Ifgd`aykd$$Ifl0L L` t0'24 lalyt`a $$Ifa$gd`a (((((((((((( )#)$)%)3)4)5)9)))ŵs`sV?s`s-jh5 CJOJQJU^JmH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jBh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH (((( )9000 $Ifgd`akd$$IflFֈL| '7k002 t0'4 lalyt`a )#)$)6)9)))SJJJ $Ifgd`akd$$Ifl\L 7k` t0'24 lalyt`a $$Ifa$gd`a)))))2*_VQQ>5<$If^`5gd`agd5 ^gd5 kd#$$IflT\L 7k` t0'24 lalyt`a))))))1*2*A*B*C*Q*R*S*T*f*g*ǶscLsc@0h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jӭh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH  h5 5OJQJ\^JmH sH h5 5CJOJQJ^J!h5 5CJOJQJ^JmH sH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ\^J2*A*B*T*W*g****yppeUHp $If^gd`a$$If^a$gd`a <$Ifgd`a $Ifgd`aykd&$$Ifl0  t0'84 lalyt`a $$Ifa$gd`ag*h*v*w*x*{*|*********************ߦߑqdWSKh5 mH sH h5 h5 5CJOJQJ^Jh5 56OJQJ^J)jh5 OJQJU^JmH sH h5 6OJQJ^J)j5h5 OJQJU^JmH sH )jh5 OJQJU^JmH sH h5 6OJQJ^JmH sH )jIh5 OJQJU^JmH sH h5 OJQJ^JmH sH #jh5 OJQJU^JmH sH ****+?8'5$If^`5gd`a<gd5 kd!$$Iflr '7&8 t0'4 lalyt`a $If^gd`a**+++++++++%,&,4,5,6,8,ķmaN7-jkh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH +++++%,;,P,a,b,yppppp $Ifgd`aykd:$$Ifl0L L` t0'84 lalyt`a $$Ifa$gd`a 8,:,;,<,J,K,L,N,O,P,a,b,c,d,r,s,t,x,,-/-ξξ|laξJ7$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH b,c,u,x,,-9000 $Ifgd`akdW$$IflFֈL| '7k008 t0'4 lalyt`a,-/-0-B-E---SJJJ $Ifgd`akd$$Ifl\L 7k` t0'84 lalyt`a $$Ifa$gd`a/-0-1-?-@-A-E-----R.T.Z.//һ⯜~ldS>))h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH "h5 CJOJQJ^JaJmH sH %h5 CJH*OJQJ^JaJmH sH h5 OJQJ\^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^J--S.T./,/_VQ@4 $$Ifa$gd`a5$If^`5gd`agd5 ^gd5 kdg$$IflT\L 7k` t0'84 lalyt`a/,/-/.//B/////////?0B0C0D0J0ϿϜ~ϿgϜ]UD!h5 5CJOJQJ^JmH sH h5 mH sH h5 OJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-j%h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J,/-/?/B///|||p $$Ifa$gd`a $Ifgd`aykdj$$Ifl0L L` t0 4 lalyt`a////?0B0_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0 4 lalyt`aB0C0D011_ZI= $$Ifa$gd`a5$If^`5gd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`aJ0111111111I2L2M2N2\2]2^2b222ȹ~r_rT=r_r-jKh5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jһh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH 1111I2L2|||p $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`aL2M2_2b222_VVVJ $$Ifa$gd`a $Ifgd`akdH$$Ifl\L 7k` t0 4 lalyt`a22222_ZI= $$Ifa$gd`a5$If^`5gd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`a2222222233333333̽vbM=v0h5 CJH*OJQJ^Jh5 CJOJQJ^JmH sH )h5 5CJOJQJ^JmH nH sH tH 'h/h5 5CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH h5 mH sH h5 OJQJ^J22333|i] $$Ifa$gd`a5<$If^`5gd`a $Ifgd`aykdľ$$Ifl0L L` t0 4 lalyt`a3334#4rm\P $$Ifa$gd`a5$If^`5gd`agd5 kd$$IflFL ` t0     4 lalyt`a333344#4$4%43444549444444ŰpYM:Mp$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 7mH sH h5 6OJQJ^J#4$4649444|||p $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a444444_VVVJ $$Ifa$gd`a $Ifgd`akd/$$Ifl\L 7k` t0 4 lalyt`a444444444 5!5051525@5ȵȫ}h[L<h5 CJOJQJ^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -j2h5 CJOJQJU^JmH sH 444!505_ZQE $$Ifa$gd`a $Ifgd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`a0515C5F555|||p $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a@5A5B5F5555555555555555ȵȪԚȵyq`K6)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 OJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jfh5 CJOJQJU^JmH sH 555555_VVVJ $$Ifa$gd`a $Ifgd`akd$$Ifl\L 7k` t0 4 lalyt`a55555_ZQE $$Ifa$gd`a $Ifgd`agd5 kdU$$Ifl\L 7k` t0 4 lalyt`a555566 6&6'6(6667686J6K6L6R66ϿϜϿzϜphWB)h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH h5 mH sH h5 OJQJ^J-j~h5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J55 6 6#6&6|||p $$Ifa$gd`a $Ifgd`aykdX$$Ifl0L L` t0 4 lalyt`a&6'696<6G6J6_VVVJ $$Ifa$gd`a $Ifgd`akd{$$Ifl\L 7k` t0 4 lalyt`aJ6K6L666_ZQE $$Ifa$gd`a $Ifgd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`a6666666667777+7,7-7177777κtiRtH@h5 mH sH h5 OJQJ^J-j+h5 CJOJQJU^JmH sH h5 6OJQJ^J$h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH 666677|||p $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0 4 lalyt`a77.71777_VVVJ $$Ifa$gd`a $Ifgd`akd($$Iflk\L 7k` t0 4 lalyt`a77778_ZI= $$Ifa$gd`a5$If^`5gd`agd5 kd$$Ifl\L 7k` t0 4 lalyt`a7777888888-8.8<8=8>8@8B8C8D8R8ķmaJ9a!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J-j_h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 5CJOJQJ\^Jh5 5CJOJQJ^J)h5 5CJOJQJ^JmH nH sH tH )h5 5CJOJQJ^JmH nH sH tH !h5 5CJOJQJ^JmH sH 8888-8C8X8i8j8|||pp|| $$Ifa$gd`a $Ifgd`aykd$$Ifl0L L` t0'84 lalyt`aR8S8T8V8W8X8i8j8k8l8z8{8|8888888ij~g[H1-jfh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jKh5 CJOJQJU^JmH sH j8k8}8889000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a8888888888888888888)9*989ӿ}mbK8$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 88888 $Ifgd`a $$Ifa$gd`a8888)99000 $Ifgd`akdR$$IflFֈL| '7k008 t0'4 lalyt`a8999:9<9>9?9@9N9O9P9R9S9T9e9f9g9h9v9w9x9ijĐreUJ3-jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -j_h5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH )9?9T9e9f9 $Ifgd`a $$Ifa$gd`af9g9y9|9$:9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`ax9|9$:%:3:4:5:7:9:::;:I:J:K:M:N:O:`:a:b:c:q:ͽͽͽ~ͽm`SC8ͽh5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jzh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J$:::O:`:a: $Ifgd`a $$Ifa$gd`aa:b:t:w:;9000 $Ifgd`akdf$$IflFֈL| '7k008 t0'4 lalyt`aq:r:s:w:;;;;;;;;;;;;;;;;ȵԥԥ}ԥfԥUH;h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -j h5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH ;;;;; $Ifgd`a $$Ifa$gd`a;;;;;;;;;Y<Z<h<i<j<l<n<o<p<~<<<<<«ŸudM<!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH !h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^JnH tH ;;;;Y<9000 $Ifgd`akd$$IflֈL| '7k008 t0'4 lalyt`aY<o<<<< $Ifgd`a $$Ifa$gd`a<<<<<<<<<<<<<<<<<<<< =ʶpYH!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J<<<<<9000 $Ifgd`akdz$$IflFֈL| '7k008 t0'4 lalyt`a<<=$=%= $Ifgd`a $$Ifa$gd`a ======$=%=&='=5=6=7=8=;=(>)>7>8>9>ijh\I2-jh5 CJOJQJU^JmH sH $h/h5 CJOJQJ^JmH sH h5 CJOJQJ^J-jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -jh5 CJOJQJU^JmH sH %=&=8=;=(>9000 $Ifgd`akd$$IflFֈL| '7k008 t0'4 lalyt`a9>;><>=>K>L>M>O>P>Q>b>c>d>e>s>t>u>v>y>>>?𨛎~s\I$h/h5 CJOJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 6OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH 'jh5 CJOJQJU^JmH sH h5 CJOJQJ^Jh5 CJOJQJ^JmH sH (><>Q>b>c> $Ifgd`a $$Ifa$gd`ac>d>v>y>>9000 $Ifgd`akdr$$IflֈL| '7k008 t0'4 lalyt`a?????????????-?.?/?0?>???@?A?ijĐreUK4-jh5 CJOJQJU^JmH sH h5 OJQJ^Jh5 CJOJQJ^JnH tH h5 5CJOJQJ^Jh5 CJH*OJQJ^J!h5 CJH*OJQJ^JmH sH -jh5 CJOJQJU^JmH sH h5 CJOJQJ^J!h5 CJH*OJQJ^JmH sH h5 CJOJQJ^JmH sH 'jh5 CJOJQJU^JmH sH -j h5 CJOJQJU^JmH sH >??-?.? $Ifgd`a $$Ifa$gd`a.?/?A?D?T?900% <$Ifgd`a $Ifgd`akd$$IflMֈL| '7k